,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,1,1,1,,137181,2179,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H23 Non-Small Cell Lung cell line,Confirmatory,,
1,3,1,1,,137181,2179,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H226 Non-Small Cell Lung cell line,Confirmatory,,
2,5,1,1,,137181,2179,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H322M Non-Small Cell Lung cell line,Confirmatory,,
3,7,1,1,,137181,2179,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H460 Non-Small Cell Lung cell line,Confirmatory,,
4,9,1,1,,137181,2179,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the HOP-62 Non-Small Cell Lung cell line,Confirmatory,,
5,11,1,1,,137181,2179,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the HOP-18 Non-Small Cell Lung cell line,Confirmatory,,
6,13,1,1,,137181,2179,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the HOP-92 Non-Small Cell Lung cell line,Confirmatory,,
7,15,1,1,,137181,2179,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H522 Non-Small Cell Lung cell line,Confirmatory,,
8,17,1,1,,137181,2179,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the LXFL 529 Non-Small Cell Lung cell line,Confirmatory,,
9,19,1,1,,137181,2179,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the A549/ATCC Non-Small Cell Lung cell line,Confirmatory,,
10,21,1,1,,137181,2179,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the EKVX Non-Small Cell Lung cell line,Confirmatory,,
11,23,1,1,,137181,2179,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the LOX IMVI Melanoma cell line,Confirmatory,,
12,25,1,1,,137181,2179,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the M14 Melanoma cell line,Confirmatory,,
13,27,1,1,,137181,2179,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the M19-MEL Melanoma cell line,Confirmatory,,
14,29,1,1,,137181,2179,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the MALME-3M Melanoma cell line,Confirmatory,,
15,31,1,1,,137181,2179,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the UACC-62 Melanoma cell line,Confirmatory,,
16,33,1,1,,137181,2179,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the UACC-257 Melanoma cell line,Confirmatory,,
17,35,1,1,,137181,2179,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-2 Melanoma cell line,Confirmatory,,
18,37,1,1,,137181,2179,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-5 Melanoma cell line,Confirmatory,,
19,39,1,1,,137181,2179,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-28 Melanoma cell line,Confirmatory,,
20,41,1,1,,137181,2179,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the PC-3 Prostate cell line,Confirmatory,,
21,43,1,1,,137181,2179,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the DU-145 Prostate cell line,Confirmatory,,
22,45,1,1,,137181,2179,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SF-268 Central Nervous System cell line,Confirmatory,,
23,47,1,1,,137181,2179,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SF-295 Central Nervous System cell line,Confirmatory,,
24,49,1,1,,137181,2179,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SF-539 Central Nervous System cell line,Confirmatory,,
25,51,1,1,,137181,2179,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the XF 498 Central Nervous System cell line,Confirmatory,,
26,53,1,1,,137181,2179,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SNB-19 Central Nervous System cell line,Confirmatory,,
27,55,1,1,,137181,2179,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SNB-75 Central Nervous System cell line,Confirmatory,,
28,57,1,1,,137181,2179,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SNB-78 Central Nervous System cell line,Confirmatory,,
29,59,1,1,,137181,2179,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the U251 Central Nervous System cell line,Confirmatory,,
30,61,1,1,,137181,2179,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the DMS 273 Small Cell Lung cell line,Confirmatory,,
31,63,1,1,,137181,2179,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the DMS 114 Small Cell Lung cell line,Confirmatory,,
32,65,1,1,,137181,2179,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HT29 Colon cell line,Confirmatory,,
33,67,1,1,,137181,2179,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the COLO 205 Colon cell line,Confirmatory,,
34,69,1,1,,137181,2179,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the DLD-1 Colon cell line,Confirmatory,,
35,71,1,1,,137181,2179,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the HCT-15 Colon cell line,Confirmatory,,
36,73,1,1,,137181,2179,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the KM12 Colon cell line,Confirmatory,,
37,75,1,1,,137181,2179,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the KM20L2 Colon cell line,Confirmatory,,
38,77,1,1,,137181,2179,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HCC-2998 Colon cell line,Confirmatory,,
39,79,1,1,,137181,2179,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the HCT-116 Colon cell line,Confirmatory,,
40,81,1,1,,137181,2179,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SW-620 Colon cell line,Confirmatory,,
41,83,1,1,,137181,2179,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the MCF7 Breast cell line,Confirmatory,,
42,85,1,1,,137181,2179,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MDA-MB-435 Breast cell line,Confirmatory,,
43,87,1,1,,137181,2179,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MDA-N Breast cell line,Confirmatory,,
44,89,1,1,,137181,2179,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the BT-549 Breast cell line,Confirmatory,,
45,91,1,1,,137181,2179,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the T-47D Breast cell line,Confirmatory,,
46,93,1,1,,137181,2179,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI/ADR-RES Breast cell line,Confirmatory,,
47,95,1,1,,137181,2179,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MDA-MB-231/ATCC Breast cell line,Confirmatory,,
48,97,1,1,,137181,2179,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HS 578T Breast cell line,Confirmatory,,
49,99,1,1,,137181,2179,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-3 Ovarian cell line,Confirmatory,,
50,101,1,1,,137181,2179,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the IGROV1 Ovarian cell line,Confirmatory,,
51,103,1,1,,137181,2179,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-OV-3 Ovarian cell line,Confirmatory,,
52,105,1,1,,137181,2179,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-4 Ovarian cell line,Confirmatory,,
53,107,1,1,,137181,2179,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-5 Ovarian cell line,Confirmatory,,
54,109,1,1,,137181,2179,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-8 Ovarian cell line,Confirmatory,,
55,111,1,1,,137181,2179,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the P388 Leukemia cell line,Confirmatory,,
56,113,1,1,,137181,2179,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the RPMI-8226 Leukemia cell line,Confirmatory,,
57,115,1,1,,137181,2179,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SR Leukemia cell line,Confirmatory,,
58,117,1,1,,137181,2179,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the P388/ADR Leukemia cell line,Confirmatory,,
59,119,1,1,,137181,2179,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the CCRF-CEM Leukemia cell line,Confirmatory,,
60,121,1,1,,137181,2179,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the K-562 Leukemia cell line,Confirmatory,,
61,123,1,1,,137181,2179,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the MOLT-4 Leukemia cell line,Confirmatory,,
62,125,1,1,,137181,2179,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the HL-60(TB) Leukemia cell line,Confirmatory,,
63,127,1,1,,137181,2179,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SN12K1 Renal cell line,Confirmatory,,
64,129,1,1,,137181,2179,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the A498 Renal cell line,Confirmatory,,
65,131,1,1,,137181,2179,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the CAKI-1 Renal cell line,Confirmatory,,
66,133,1,1,,137181,2179,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the RXF 393 Renal cell line,Confirmatory,,
67,135,1,1,,137181,2179,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the RXF-631 Renal cell line,Confirmatory,,
68,137,1,1,,137181,2179,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the 786-0 Renal cell line,Confirmatory,,
69,139,1,1,,137181,2179,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the ACHN Renal cell line,Confirmatory,,
70,141,1,1,,137181,2179,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the TK-10 Renal cell line,Confirmatory,,
71,143,1,1,,137181,2179,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the UO-31 Renal cell line,Confirmatory,,
72,145,1,1,,137181,2179,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SN12C Renal cell line,Confirmatory,,
73,179,1,1,,137181,2179,Inactive,,,,,NCI AIDS Antiviral Assay,Confirmatory,,
74,182,1,1,,137181,2179,Inconclusive,,,,,"NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia resistant to Adriamycin; NSC 123127, Developed at Scr 06 and 41 (intraperitoneal) in B6D2F1 (BDF1) mice",Other,,
75,184,1,1,,137181,2179,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  ADJ-PC-6 (intraperitoneal) in BALB/cJ mice,Other,,
76,186,1,1,,137181,2179,Unspecified,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Nontumored Animals (Toxicity Test) in B6D2F1 (BDF1) mice,Other,,
77,188,1,1,,137181,2179,Unspecified,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Nontumored Animals (Toxicity Test) in CD2F1 (CDF1) mice,Other,,
78,192,1,1,,137181,2179,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  B16 Melanoma (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
79,194,1,1,,137181,2179,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  B16 Melanoma (subcutaneous) in B6D2F1 (BDF1) mice,Other,,
80,196,1,1,,137181,2179,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  B16 Melanoma (intracerebral) in B6D2F1 (BDF1) mice,Other,,
81,200,1,1,,137181,2179,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  B16 Melanoma (intraperitoneal) in B6C3F1 mice,Other,,
82,206,1,1,,137181,2179,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  HT29;CX-1 Human Adenocarcinoma (MER+) (intrarenal inoculation) in NU/NU Swiss (nude) mice,Other,,
83,210,1,1,,137181,2179,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Colon 26 Adenocarcinoma (intraperitoneal) in CD2F1 (CDF1) mice,Other,,
84,212,1,1,,137181,2179,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Colon Carcinoma 38 (subcutaneous) in B6D2F1 (BDF1) mice,Other,,
85,220,1,1,,137181,2179,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Mammary Adenocarcinoma CD8F1 (subcutaneous) in CD8F1,Other,,
86,222,1,1,,137181,2179,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Ependymoblastoma (intracerebral) in C57BL/6 mice,Other,,
87,226,1,1,,137181,2179,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Ependymoblastoma (intracerebral) in B6C3F1 mice,Other,,
88,248,1,1,,137181,2179,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
89,252,1,1,,137181,2179,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (intracerebral) in B6D2F1 (BDF1) mice,Other,,
90,256,1,1,,137181,2179,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (intraperitoneal) in CD2F1 (CDF1) mice,Other,,
91,264,1,1,,137181,2179,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Human Lung LX-1 Xenograft (intrarenal inoculation) in NU/NU Swiss (nude) mice,Other,,
92,270,1,1,,137181,2179,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Lewis Lung Carcinoma (subcutaneous) in B6D2F1 (BDF1) mice,Other,,
93,274,1,1,,137181,2179,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Lewis Lung Carcinoma (intravenous) in B6D2F1 (BDF1) mice,Other,,
94,280,1,1,,137181,2179,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Human Amelanotic Melanoma (LOX) (intraperitoneal) in NU/NU BALB/C (nude) mice,Other,,
95,288,1,1,,137181,2179,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Sarcoma M5076 (subcutaneous) in B6D2F1 (BDF1) mice,Other,,
96,292,1,1,,137181,2179,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Sarcoma M5076 (intraperitoneal) in B6C3F1 mice,Other,,
97,294,1,1,,137181,2179,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Human Mammary Carcinoma MX-1 Xenograft (subcutaneous) in NU/NU Swiss (nude) mice,Other,,
98,296,1,1,,137181,2179,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Human Mammary Carcinoma MX-1 Xenograft (intrarenal inoculation) in NU/NU Swiss (nude) mice,Other,,
99,322,1,1,,137181,2179,Inactive,,,,,"NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia resistant to Adriamycin; NSC 123127, Developed at Scr 08 (intraperitoneal) in CD2F1 (CDF1) mice",Other,,
100,324,1,1,,137181,2179,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia resistant to AMSA; NSC 249992 (intraperitoneal) in CD2F1 (CDF1) mice,Other,,
101,326,1,1,,137181,2179,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia resistant to Dihydroxy Anthracenedione; NSC 299195 (intraperitoneal) in CD2F1 (CDF1) mice,Other,,
102,328,1,1,,137181,2179,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
103,330,1,1,,137181,2179,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia (intraperitoneal) in CD2F1 (CDF1) mice,Other,,
104,336,1,1,,137181,2179,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia resistant to Vincristine; NSC 67574 (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
105,357,2,1,,11110803,2179,Inactive,,,,,AP1 Signaling Pathway,Confirmatory,,
106,410,1,5,,11110803,2179,Active,73915100.0,1544.0,,,p450-cyp1a2,Confirmatory,,
107,411,2,1,,11110803,2179,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
108,444,1,1,,11110803,2179,Inconclusive,,,,,NFAT Signaling Pathway,Confirmatory,,
109,445,3,1,,11110803,2179,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
110,446,1,1,,11110803,2179,Inconclusive,,,,,Stat Signaling Pathway,Confirmatory,,
111,447,1,1,,11110803,2179,Inconclusive,,,,,O-Glc NAc Transferase (sOGT),Confirmatory,,
112,448,1,2,,11110803,2179,Inactive,4325211.0,,,,Schistosoma Mansoni Peroxiredoxins (Prx2),Confirmatory,,
113,450,1,2,,11110803,2179,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
114,451,1,2,,11110803,2179,Inactive,66528677.0,2908.0,,,GR-EFC Redistribution,Confirmatory,,
115,526,1,1,,11110803,2179,Inactive,,,,,Ubiquitin-GFP Assay,Confirmatory,,
116,530,1,1,,11110803,2179,Inconclusive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
117,584,1,3,,11110803,2179,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
118,585,1,4,,11110803,2179,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
119,587,1,5,,11110803,2179,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Texas Red Spectral Region,Other,,
120,588,1,4,,11110803,2179,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Resorufin Spectral Region,Other,,
121,589,1,3,,11110803,2179,Active,,,,,qHTS Assay for Spectroscopic Profiling in 4-MU Spectral Region,Other,,
122,590,1,3,,11110803,2179,Active,,,,,qHTS Assay for Spectroscopic Profiling in A350 Spectral Region,Other,,
123,591,1,4,,11110803,2179,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A488 Spectral Region,Other,,
124,592,1,6,,11110803,2179,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A647 Spectral Region,Other,,
125,593,1,4,,11110803,2179,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Fluorescein Spectral Region,Other,,
126,594,1,4,,11110803,2179,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Rhodamine Spectral Region,Confirmatory,,
127,595,1,3,,11110803,2179,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
128,596,1,2,,11110803,2179,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
129,597,1,3,,11110803,2179,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
130,603,1,2,,11110803,2179,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
131,605,1,2,,11110803,2179,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
132,607,1,3,,11110803,2179,Inactive,82799486.0,5142.0,,,qHTS Assay for Inhibitors of PDE-IV,Confirmatory,,
133,662,1,1,,11110803,2179,Active,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
134,875,1,2,,11110803,2179,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
135,879,1,2,,11110803,2179,Inactive,3290016.0,6002.0,,Potency,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Green Fluorophore),Confirmatory,,
136,879,1,2,,11110803,2179,Inactive,33946324.0,2770.0,,Potency,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Green Fluorophore),Confirmatory,,
137,881,2,2,,11110803,2179,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
138,883,1,3,,11110803,2179,Inactive,13699818.0,1559.0,12.5893,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9,Confirmatory,,
139,884,1,2,,11110803,2179,Inconclusive,13435386.0,1576.0,19.9526,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
140,885,1,2,,11110803,2179,Inactive,13435386.0,1576.0,19.9526,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
141,886,1,2,,11110803,2179,Active,122921310.0,,31.6228,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
142,886,1,2,,11110803,2179,Active,122921311.0,,31.6228,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
143,887,1,2,,11110803,2179,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
144,889,1,3,,11110803,2179,Inconclusive,1730092.0,840.0,15.8489,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
145,891,1,2,,11110803,2179,Inactive,40805836.0,1565.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2D6,Confirmatory,,
146,892,1,2,,11110803,2179,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
147,893,1,2,,11110803,2179,Active,122921310.0,,31.6228,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
148,893,1,2,,11110803,2179,Active,122921311.0,,31.6228,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
149,895,1,2,,11110803,2179,Inconclusive,21620132.0,4790.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for NFkB Signaling Pathway,Confirmatory,,
150,899,1,2,,11110803,2179,Inactive,4503219.0,1557.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C19,Confirmatory,,
151,900,1,3,,11110803,2179,Inconclusive,15431328.0,834.0,15.8489,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
152,901,1,2,,11110803,2179,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors,Confirmatory,,
153,902,1,2,,11110803,2179,Inconclusive,120407068.0,7157.0,7.9433,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
154,912,1,2,,11110803,2179,Inconclusive,21392848.0,,12.5893,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
155,914,1,3,,11110803,2179,Inconclusive,32879895.0,3091.0,5.0119,Potency,qHTS Assay for Identification of Small Molecule Agonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
156,915,1,3,,11110803,2179,Inconclusive,32879895.0,3091.0,5.0119,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
157,917,1,3,,11110803,2179,Inconclusive,120660324.0,7066.0,2.5119,Potency,qHTS Assay for Identification of Small Molecule Agonists for Thrombopoietin (TPO) Signaling Pathway,Confirmatory,,
158,918,1,3,,11110803,2179,Inconclusive,120660324.0,7066.0,2.5119,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Thrombopoietin (TPO) Signaling Pathway,Confirmatory,,
159,922,1,2,,11110803,2179,Inconclusive,15724400.0,6778.0,25.1189,Potency,Confirmation Concentration-Response Assay for Identification of Small Molecule Antagonists of Stat Signaling Pathway,Confirmatory,,
160,923,1,2,,11110803,2179,Inconclusive,,,15.8489,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
161,924,1,2,,11110803,2179,Inconclusive,120407068.0,7157.0,1.0,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
162,925,1,2,,11110803,2179,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
163,926,1,2,,11110803,2179,Inconclusive,38016895.0,7253.0,39.8107,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
164,927,1,3,,11110803,2179,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
165,928,1,2,,11110803,2179,Inconclusive,21620132.0,4790.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for NFkB Signaling Pathway,Confirmatory,,
166,934,1,2,,11110803,2179,Inconclusive,15724400.0,6778.0,25.1189,Potency,Parental Cell Counter Screen for Stat Signaling Pathway Assay,Confirmatory,,
167,935,1,3,,11110803,2179,Inconclusive,15724400.0,6778.0,25.1189,Potency,Confirmation Concentration-Response Assay for Identification of Small Molecule Agonists of Stat Signaling Pathway,Confirmatory,,
168,938,1,2,,11110803,2179,Inconclusive,38016895.0,7253.0,39.8107,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
169,943,1,2,,11110803,2179,Inconclusive,18249941.0,25229.0,6.3096,Potency,qHTS Assay for Antagonists of Acetylcholine Muscarinic M1 Receptor: Kinetic Measurement of Intracellular Calcium Response,Confirmatory,,
170,944,1,2,,11110803,2179,Active,18249941.0,25229.0,10.0,Potency,qHTS Assay for Antagonists of Acetylcholine Muscarinic M1 Receptor: Measurement of IP-One Response,Confirmatory,,
171,945,1,4,,11110803,2179,Inactive,290753097.0,,,Potency,qHTS Validation Assay for Inhibitors of Leishmania Mexicana Pyruvate Kinase,Confirmatory,,
172,954,1,2,,11110803,2179,Inactive,33286420.0,5315.0,,Potency,qHTS Assay for Activators of Human Muscle Pyruvate Kinase,Confirmatory,,
173,957,1,2,,11110803,2179,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Coffee Bean alpha-Galactosidase at pH 4.5,Confirmatory,,
174,958,1,2,,11110803,2179,Inactive,33286420.0,5315.0,,Potency,qHTS Assay for Inhibitors of Human Muscle Pyruvate Kinase,Confirmatory,,
175,959,1,4,,11110803,2179,Inactive,290753097.0,,,Potency,qHTS Validation Assay for Activators of Leishmania Mexicana Pyruvate Kinase,Confirmatory,,
176,992,1,3,,11110803,2179,Inactive,757912.0,2717.0,44.6684,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Human alpha-Galactosidase at pH 4.5,Confirmatory,,
177,995,1,2,,11110803,2179,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
178,997,1,2,,11110803,2179,Inactive,52076901.0,4341833.0,44.6684,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Rice alpha-Glucosidase at pH 5.0,Confirmatory,,
179,998,1,2,,11110803,2179,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Coffee Bean alpha-Galactosidase at pH 5.9,Confirmatory,,
180,1195,1,2,,48415564,2179,Active,,,,,DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database,Other,,
181,1452,1,1,,11110803,2179,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
182,1471,2,1,,11110803,2179,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
183,1851,1,2,,11110803,2179,Unspecified,,,,,Cytochrome panel assay with activity outcomes,Other,,
184,1851,1,2,1.0,11110803,2179,Inactive,4503219.0,1557.0,,,Cytochrome panel assay with activity outcomes,Other,,
185,1851,1,2,2.0,11110803,2179,Inactive,68509921.0,1565.0,,,Cytochrome panel assay with activity outcomes,Other,,
186,1851,1,2,3.0,11110803,2179,Inconclusive,13435386.0,1576.0,,,Cytochrome panel assay with activity outcomes,Other,,
187,1851,1,2,4.0,11110803,2179,Active,73915100.0,1544.0,,,Cytochrome panel assay with activity outcomes,Other,,
188,1851,1,2,5.0,11110803,2179,Inconclusive,13699818.0,1559.0,,,Cytochrome panel assay with activity outcomes,Other,,
189,2660,1,1,,90341308,2179,Inconclusive,4826730.0,2475.0,0.1309,Potency,"Cytometric Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
190,2666,1,1,,90341308,2179,Inactive,4826730.0,2475.0,,Potency,"High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
191,2667,1,1,,90341308,2179,Active,4826730.0,2475.0,3.6898,Potency,High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF Cells,Confirmatory,,
192,2668,1,1,,90341308,2179,Active,4826730.0,2475.0,0.5212,Potency,Cytometry Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF cells,Confirmatory,,
193,8681,6,2,,103166066,2179,Active,,,0.03,IC50,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),Confirmatory,10780913.0,
194,9989,6,2,,103166066,2179,Active,,,0.35,IC50,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,Confirmatory,9871638.0,
195,10004,6,2,,103166066,2179,Active,,,0.1,IC50,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,Confirmatory,7658436.0,
196,18955,3,4,,103166066,2179,Unspecified,,,,,Lipophilicity index (substitution method),Other,9258370.0,
197,19530,7,1,,103166066,2179,Unspecified,,,,,Half-life was evaluated in water in the absence of light,Other,2157014.0,
198,19531,7,1,,103166066,2179,Unspecified,,,,,Half-life was evaluated in water in the presence of light,Other,2157014.0,
199,20508,3,4,,103166066,2179,Unspecified,,,,,Chromatographic measure of drug lipophilicity,Other,6688830.0,
200,20511,3,4,,103166066,2179,Unspecified,,,,,Lipophilicity (Rm) (liquid chromatography),Other,6747989.0,
201,20524,3,4,,103166066,2179,Unspecified,,,,,Relative measure (Rm) of lipophilic/hydrophilic balance from partition chromatography,Other,6988589.0,
202,20525,3,4,,103166066,2179,Unspecified,,,,,Lipophilicity (Rm).,Other,3625706.0,
203,22554,4,1,,103166066,2179,Unspecified,,,,,Susceptibility to thiolytic cleavage: T1/2 in presence of excess 2-mercaptoethanol,Other,6894620.0,
204,23103,3,3,,103166066,2179,Unspecified,,,,,The compound was evaluated for its acid dissociation constant,Other,3625706.0,
205,25311,3,3,,103166066,2179,Unspecified,,,,,Acid dissociation constant was determined,Other,6688830.0,
206,25353,3,4,,103166066,2179,Unspecified,,,,,"Compound was evaluated for its rate of absorption from the intestine and pKa value was determined, lower value indicate high absorption from gastrointestinal tract.",Other,6546590.0,
207,25369,3,3,,103166066,2179,Unspecified,,,,,Compound was evaluated for the protonation constant by binding to DNA by intercalation in calf thymus.,Other,1992157.0,
208,25559,3,3,,103166066,2179,Unspecified,,,,,Ionization constant (pKa),Other,7069706.0,
209,25575,3,4,,103166066,2179,Unspecified,,,,,Dissociation constant in aqueous DMF.,Other,6546591.0,
210,25641,5,2,,103166066,2179,Unspecified,,,,,Half life of the drug was determined in the presence of 2-mercaptoethanol,Other,6688830.0,
211,25818,3,3,,103166066,2179,Unspecified,,,,,Ionisation constant (pKa),Other,6894620.0,
212,26064,3,4,,103166066,2179,Unspecified,,,,,Ionization constant (pKa),Other,6988589.0,
213,26314,3,3,,103166066,2179,Unspecified,,,,,pKa value determined spectrophotometrically in 20% aqueous DMF,Other,6688829.0,
214,26528,3,3,,103166066,2179,Unspecified,,,,,Binding affinity towards poly[d(A-T)] (fluorometric method),Other,6747989.0,
215,26756,3,4,,103166066,2179,Unspecified,,,,,DNA binding dissociation constant as KD,Other,6708048.0,
216,29364,3,3,,103166066,2179,Unspecified,,,,,pKa values were determined spectrophotometrically in 20% DMF.,Other,3560159.0,
217,35545,3,3,,103166066,2179,Unspecified,,,,,"Ability to block cleavage of AG/CT site in AluI enzyme with the test compound, DNA ratio 1(no. of sites=16); - = no activation",Other,2157014.0,
218,35546,3,3,,103166066,2179,Unspecified,,,,,"Ability to block cleavage of AG/CT site in AluI enzyme with the test compound, DNA ratio 1:8(no. of sites=16); - = no activation",Other,2157014.0,
219,35547,3,3,,103166066,2179,Unspecified,,,,,"Ability to block cleavage of AG/CT site in AluI enzyme with the test compound, DNA ratio 4(no. of sites=16); - = no activation",Other,2157014.0,
220,43704,6,2,,103166066,2179,Unspecified,,,130.0,IC50,Cytotoxicity in human leukemic CCRF-CEM cells.,Confirmatory,14667232.0,
221,43838,6,2,,103166066,2179,Active,,,0.139,IC50,The compound was tested for the cytotoxicity against human leukemic CCRF-CEM cell lines,Confirmatory,7650675.0,
222,45745,4,4,,103166066,2179,Active,,,0.0006,IC50,Inhibitory activity of compound for AA8 cells to reduce cell density by 50% (exposed to compound for 4 hours),Confirmatory,2909741.0,
223,46155,6,2,,103166066,2179,Active,,,11.0,EC50,In vitro evaluation for intercalating potency by using calf thymus DNA in ethidium bromide displacement assay,Confirmatory,9733489.0,
224,47003,6,2,,103166066,2179,Active,,,0.52,IC50,The compound was tested for the cytotoxicity against human leukemic CEM/VBL cell lines,Confirmatory,7650675.0,
225,47006,6,2,,103166066,2179,Active,,,1.91,IC50,The compound was tested for the cytotoxicity against human leukemic CEM/VM-1 cell lines,Confirmatory,7650675.0,
226,51931,6,2,,103166066,2179,Active,,,0.24,IC50,Tested for the cytotoxicity against the repair deficient xrs-6 chinese hamster ovary cell line,Confirmatory,7525959.0,
227,53293,3,7,,103166066,2179,Unspecified,,,,,Compound was tested for DNA Topoisomerase II mediated cleavage of DNA; Each (+) indicates 1 to 2 -fold increase,Other,7241506.0,
228,53603,6,2,,103166066,2179,Active,,,0.004,IC50,The compound was tested for the cytotoxicity DC-3F cell lines,Confirmatory,7650675.0,
229,53621,6,2,,103166066,2179,Active,,,0.047,IC50,"The compound was tested for the cytotoxicity against human leukemic DC-3F/ADII cell lines, activity is expressed as IC50 values.",Confirmatory,7650675.0,
230,54240,5,2,,103166066,2179,Unspecified,,,,,Fraction of the observed equilibrium absorbance change accounted in the kinetic analysis.,Other,2362284.0,
231,54263,4,4,,103166066,2179,Unspecified,,,,,DNA-bound drug concentration in 0.1 SHE buffer at the concentration of 50 uM for equilibrium binding to calf thymus DNA,Other,2362284.0,
232,54264,3,4,,103166066,2179,Unspecified,,,,,Free drug concentration in 0.1 SHE buffer at the concentration of 50 uM for equilibrium binding to calf thymus DNA,Other,2362284.0,
233,54265,3,4,,103166066,2179,Unspecified,,,,,Free drug concentration in 0.1 SHE buffer at the concentration of 50 uM; 9.4 x 10 e-3 epcilonfor equilibrium binding to calf thymus DNA,Other,2362284.0,
234,54266,4,4,,103166066,2179,Unspecified,,,,,Micelle-bound drug concentration in 0.1 SHE buffer at the concentration of 50 uM for equilibrium binding to calf thymus DNA,Other,2362284.0,
235,54435,6,3,,103166066,2179,Active,,,11.0,EC50,DNA intercalation potency using ethidium bromide displacement assay in calf thymus,Confirmatory,,
236,54437,9,3,,103166066,2179,Active,,,11.0,EC50,Inhibition of calf thymus DNA/ethidium bromide complex formation.,Confirmatory,,
237,54456,3,3,,103166066,2179,Unspecified,,,,,Binding constant to poly (dA-dT) was determined in calf thymus DNA by a fluorometric method,Other,6688830.0,
238,54658,7,1,,103166066,2179,Active,,,,,Inhibitory concentration against ethidium in DNA-binding assay,Other,7658436.0,
239,54960,5,2,,103166066,2179,Unspecified,,,,,Percentage of the sum of the amplitudes in the kinetic experiment.,Other,2362284.0,
240,54990,3,3,,103166066,2179,Unspecified,,,,,Change in DNA-melting (deltaTm) with calf thymus DNA at pH 7.0,Other,7658436.0,
241,55008,3,3,,103166066,2179,Unspecified,,,,,Association constant measured for binding towards poly[d(A-T)] of DNA in calf thymus,Other,6894620.0,
242,55121,3,3,,103166066,2179,Unspecified,,,,,Binding constant (log K) for DNA binding by ethidium bromide displacement,Other,3755758.0,
243,55122,4,3,,103166066,2179,Unspecified,,,,,Binding constant (log K) for DNA by ethidium bromide displacement,Other,3560159.0,
244,55124,3,3,,103166066,2179,Unspecified,,,,,Binding constant for DNA by ethidium bromide displacement,Other,6546591.0,
245,55134,3,3,,103166066,2179,Unspecified,,,,,Binding constant for DNA by ethidium bromide displacement,Other,3625706.0,
246,55137,4,3,,103166066,2179,Unspecified,,,,,DNA binding affinity as log K value,Other,6546590.0,
247,55304,6,2,,103166066,2179,Active,,,8.9,CC50,Inhibitory concentration against DNA-bound ethidium for cytotoxicity,Confirmatory,7658436.0,
248,55630,3,3,,103166066,2179,Unspecified,,,,,Induced change in DNA-melting (deltaTm) with [poly(dA-dT)]2 at pH 65.0,Other,7658436.0,
249,55643,3,4,,103166066,2179,Unspecified,,,,,Binding constant to poly[d(AT)] by ethidium bromide displacement,Other,2153829.0,
250,55650,6,2,,103166066,2179,Unspecified,,,,,Time constant describing the association profile of calf thymus DNA-drug complexes in 0.1 SHE buffer at 20 degree C after 1 min; too fast to measure,Other,2362284.0,
251,55652,5,2,,103166066,2179,Unspecified,,,,,Time constant describing the association profile of calf thymus DNA-drug complexes in 0.1 SHE buffer at 20 degree C after 2 min; too fast to measure,Other,2362284.0,
252,55657,4,4,,103166066,2179,Unspecified,,,,,Time constant describing the dissociation profile of calf thymus DNA-drug complexes in 0.1 SHE buffer at 20 degree C,Other,2362284.0,
253,57063,11,1,,103166066,2179,Active,,,0.72,EC50,In vitro inhibitior of human DNA topoisomerase II from HeLa cells.,Confirmatory,9733489.0,
254,57198,9,2,,103166066,2179,Active,,,1.0,IC50,In vitro 50% inhibition of topoisomerase II mediated k-DNA decatenation,Confirmatory,7650675.0,
255,57199,5,4,,103166066,2179,Active,,,,,In vitro inhibition of partially purified human ovarian carcinoma topoisomerase II of kDNA decatenation,Other,7473578.0,
256,57541,4,5,,103166066,2179,Active,,,1.4852,IC50,Inhibitory concentration required for cytotoxicity in DOX-resistant (DOX/R) cells,Confirmatory,,
257,65959,3,3,,103166066,2179,Unspecified,,,,,Ability to block cleavage of TTT/AAA site in DraI enzyme with the test compound/DNA ratio 1(no. of sites=3); - = no activation,Other,2157014.0,
258,65960,3,3,,103166066,2179,Unspecified,,,,,Ability to block cleavage of TTT/AAA site in DraI enzyme with the test compound/DNA ratio 1:8(no. of sites=3); - = no activation,Other,2157014.0,
259,65961,3,3,,103166066,2179,Unspecified,,,,,Ability to block cleavage of TTT/AAA site in DraI enzyme with the test compound/DNA ratio 4(no. of sites=3); - = no activation,Other,2157014.0,
260,68776,6,2,,103166066,2179,Active,,,0.04,IC50,Inhibitory activity against F460pv8/eto cell line using MTT assay,Confirmatory,10780913.0,
261,78419,6,2,,103166066,2179,Active,,,0.2,IC50,Inhibitory activity against H460pv8 cell line using MTT assay,Confirmatory,10780913.0,
262,78828,4,4,,103166066,2179,Active,,,0.12,IC50,In vitro for the inhibition of human colon tumor (HCT-8) cells.,Confirmatory,3560159.0,
263,78992,4,4,,103166066,2179,Active,,,0.12,IC50,In vitro for cytotoxicity against human colon tumor cells (HCT-8) in culture,Confirmatory,3755758.0,
264,80680,6,2,,103166066,2179,Active,,,6.3,IC50,Cytotoxicity against HCT116 cells.,Confirmatory,7473578.0,
265,80703,6,2,,103166066,2179,Active,,,6.3,IC50,Tested for the cytotoxicity to inhibit replication assay against the human colon tumor cell line HCT116,Confirmatory,7525959.0,
266,81631,6,2,,103166066,2179,Active,,,0.021,IC50,In vitro cytotoxicity against human leukemic HL-60 cell line.,Confirmatory,7650675.0,
267,82834,6,2,,103166066,2179,Active,,,0.4,IC50,Cell cytotoxicity was determined against human promyelocytic leukemia (HL60) cell line,Confirmatory,9871638.0,
268,85626,3,3,,103166066,2179,Unspecified,,,,,Ability to block cleavage of GG/CC site in HaeIII enzyme with the test compound/DNA ratio 1(no. of sites=22); - = no activation,Other,2157014.0,
269,85627,3,3,,103166066,2179,Unspecified,,,,,Ability to block cleavage of GG/CC site in HaeIII enzyme with the test compound/DNA ratio 1:8(no. of sites=22); - = no activation,Other,2157014.0,
270,85628,3,3,,103166066,2179,Unspecified,,,,,Ability to block cleavage of GG/CC site in HaeIII enzyme with the test compound/DNA ratio 4(no. of sites=22); - = no activation,Other,2157014.0,
271,88457,3,3,,103166066,2179,Unspecified,,,,,Ability to block cleavage of G/ANTC site in Hinf1 enzyme with the test compound/DNA ratio 1(no. of sites=10); - = no activation,Other,2157014.0,
272,88458,3,3,,103166066,2179,Unspecified,,,,,Ability to block cleavage of G/ANTC site in Hinf1 enzyme with the test compound/DNA ratio 1:8(no. of sites=10); - = no activation,Other,2157014.0,
273,88459,3,3,,103166066,2179,Unspecified,,,,,Ability to block cleavage of G/ANTC site in Hinf1 enzyme with the test compound/DNA ratio 4(no. of sites=10); - = no activation,Other,2157014.0,
274,91017,3,3,,103166066,2179,Unspecified,,,,,Ability to block cleavage of C/CGG site in HpaII enzyme with the test compound/DNA ratio 1(no. of sites=26); - = no activation,Other,2157014.0,
275,91018,3,3,,103166066,2179,Unspecified,,,,,Ability to block cleavage of C/CGG site in HpaII enzyme with the test compound/DNA ratio 1:8(no. of sites=26); - = no activation,Other,2157014.0,
276,91019,3,3,,103166066,2179,Unspecified,,,,,Ability to block cleavage of C/CGG site in HpaII enzyme with the test compound/DNA ratio 4(no. of sites=26); - = no activation,Other,2157014.0,
277,91784,4,5,,103166066,2179,Active,,,0.9006,IC50,Inhibitory concentration required for cytotoxicity in J774.2 murine macrophage-like cells,Confirmatory,,
278,91915,4,4,,103166066,2179,Active,,,0.037000000000000005,IC50,Inhibitory activity against Jurkat human leukemia cells,Confirmatory,11384245.0,
279,91916,4,5,,103166066,2179,Active,,,0.037000000000000005,IC50,Inhibitory concentration against Human Jurkat leukemia (JLC) cell proliferation,Confirmatory,9207945.0,
280,91917,4,4,,103166066,2179,Active,,,0.037000000000000005,IC50,"Inhibitory concentration required to reduce human Jurkat leukemia (JLC sensitive, wild type) cell number to 50% of control cultures",Confirmatory,9191970.0,
281,95291,4,4,,103166066,2179,Active,,,0.037000000000000005,IC50,Concentration required to inhibit 50% growth of human Jurkat cells,Confirmatory,10395479.0,
282,95454,6,2,,103166066,2179,Active,,,1.0,IC50,"Concentration required to reduce growth of human jurkat leukemia cells to 50% of control cultures, determined using a 72 hr continuous exposure",Confirmatory,8182707.0,
283,95456,6,2,,103166066,2179,Active,,,0.2,IC50,Concentration required to reduce the growth of human Jurkat cells to 50% of control cultures,Confirmatory,9258370.0,
284,96055,3,3,,103166066,2179,Active,,,,,Activity of the topoisomerase II dependent DNA cleavage; Active,Other,2542558.0,
285,96210,3,4,,103166066,2179,Unspecified,,,,,Percent fluorescence of the ethidium bromide-DNA complex,Other,2542558.0,
286,96372,6,2,,103166066,2179,Unspecified,,,,,Inhibition of KB cell growth in vitro,Other,2542558.0,
287,96566,6,2,,103166066,2179,Active,,,0.05,IC50,Inhibitory concentration against L1210 leukemic cell proliferation over 24 hr,Confirmatory,7658436.0,
288,96632,5,1,,103166066,2179,Active,,,0.035,ID50,In vitro test for 50% reduction of cell number (of control) after 70 hr incubation with cultures of murine L1210 leukemia cells,Confirmatory,6747989.0,
289,96646,5,1,,103166066,2179,Active,,,0.035,ID50,Concentration for inhibiting the growth of L1210 cells by 50% over 3 days was determined,Confirmatory,7143362.0,
290,96799,5,1,,103166066,2179,Active,,,0.035,ID50,In vitro concentration required to reduce the murine L1210 leukemia cells in cultures to 50% after a period of 72 hr.,Confirmatory,6546590.0,
291,97604,4,5,,103166066,2179,Unspecified,,,,,Tumor cell selectivity determined as maximal percent increase in life span (ILSmax) at LD10 dosage level in L1210 cells,Other,7120279.0,
292,98133,4,4,,103166066,2179,Active,,,0.033,IC50,In vitro for cytotoxicity against murine leukemia cells (L1210),Confirmatory,3755758.0,
293,98378,4,4,,103166066,2179,Active,,,0.033,IC50,In vitro inhibitory activity against Murine leukemia (L1210),Confirmatory,3560159.0,
294,98699,5,1,,103166066,2179,Active,,,0.035,ID50,Reduce in the cell count when drug added to the murine L1210 leukemia cell cultures for 70 h,Confirmatory,6688830.0,
295,98700,5,1,,103166066,2179,Active,,,0.035,ID50,Growth inhibition against cultured murine L1210 leukemia cells,Confirmatory,6688829.0,
296,98819,4,5,,103166066,2179,Unspecified,,,,,Drug concentration in mole/kg/day providing 50% extension of life in intraperitoneally implanted leukemia L1210 mice.,Other,7069706.0,
297,99252,3,4,,103166066,2179,Unspecified,,,,,Median survival time per control mice with leukemia P388 at 10 mg/kg dose injected intraperitoneally,Other,2542558.0,
298,99255,3,4,,103166066,2179,Unspecified,,,,,Median survival time per control mice with leukemia P388 at 20 mg/kg dose injected intraperitoneally,Other,2542558.0,
299,99259,3,4,,103166066,2179,Unspecified,,,,,Median survival time per control mice with leukemia P388 at 40 mg/kg dose injected intraperitoneally,Other,2542558.0,
300,100108,4,4,,103166066,2179,Active,,,0.012,IC50,Inhibitory activity against Lewis lung carcinoma cells,Confirmatory,11384245.0,
301,100239,4,5,,103166066,2179,Active,,,0.012,IC50,Inhibitory concentration against Murine Lewis lung carcinoma (LLC) cell proliferation,Confirmatory,9207945.0,
302,100240,4,4,,103166066,2179,Active,,,0.012,IC50,Inhibitory concentration required to reduce Lewis lung carcinoma cell number to 50% of control cultures,Confirmatory,9191970.0,
303,100911,6,2,,103166066,2179,Active,,,1.5,IC50,Concentration required to reduce incorporation of [3H]TdR in drug-treated cultures of intracellular Leishmania major to 50% of controls,Confirmatory,9258370.0,
304,101091,5,1,,103166066,2179,Active,,,0.035,ID50,In vitro concentration required to inhibit the growth of L1210 cells in culture by 50% following a 48 hr exposure.,Confirmatory,6546591.0,
305,101620,6,2,,103166066,2179,Active,,,0.49,IC50,"Inhibitory activity against MDA-468 cell line using MTT assay (ER-, amplified EGFR, mutant p53)",Confirmatory,10780913.0,
306,103073,6,2,,103166066,2179,Active,,,0.075,IC50,"Inhibitory activity against MCF-7 wt cell line using MTT assay (ER+,pgR+,wildtype p53)",Confirmatory,10780913.0,
307,103106,4,4,,103166066,2179,Active,,,0.012,IC50,Inhibitory activity of tested against Murine Lewis lung carcinoma,Confirmatory,10395479.0,
308,103235,6,3,,103166066,2179,Active,,,1.165,IC50,Inhibitory activity against MCF-7/adr cell line using MTT assay,Confirmatory,10780913.0,
309,103274,6,2,,103166066,2179,Active,,,0.075,IC50,Inhibitory activity against MCF7wt cell line using MTT assay,Confirmatory,10780913.0,
310,103447,5,2,,103166066,2179,Unspecified,,,,,Evaluated in vivo for antitumor activity against Lewis lung carcinoma; g denotes ILS of 50% could not be reached at any dose level,Other,3755758.0,
311,103470,3,6,,103166066,2179,Unspecified,,,,,In vivo for antitumor activity against Lewis lung carcinoma,Other,3755758.0,
312,103477,3,5,,103166066,2179,Unspecified,,,,,In vivo antitumor activity against Lewis lung carcinoma cells expressed as percent increase in lifespan at an optimal dose of 13.3 mg/kg/day,Other,3560159.0,
313,103617,3,5,,103166066,2179,Unspecified,,,,,In vivo for antitumor activity against Lewis lung carcinoma,Other,3755758.0,
314,104131,6,2,,103166066,2179,Active,,,0.14,IC50,"Inhibitory activity against MDA-231 cell line using MTT assay (ER-,EGFR+,mutant p53)",Confirmatory,10780913.0,
315,107797,3,4,,103166066,2179,Unspecified,,,,,Induction frequency for L5178Y cells was evaluated at dose 0.005 mg/mL in dark condition (expt-II),Other,2157014.0,
316,107798,3,4,,103166066,2179,Unspecified,,,,,Induction frequency for L5178Y cells was evaluated at dose 0.005 mg/mL in light condition (expt-II),Other,2157014.0,
317,107799,3,4,,103166066,2179,Unspecified,,,,,Mean value of mutation induction for L5178Y cells was evaluated at dose 0.005 mg/mL in dark condition (expt-II),Other,2157014.0,
318,107800,3,4,,103166066,2179,Unspecified,,,,,Mean value of mutation induction for L5178Y cells was evaluated at dose 0.005 mg/mL in light condition (expt-II),Other,2157014.0,
319,107801,6,1,,103166066,2179,Unspecified,,,,,Mutation frequency for L5178Y cells was evaluated at dose 0.005 mg/mL in dark condition (expt-II),Other,2157014.0,
320,107802,6,1,,103166066,2179,Unspecified,,,,,Mutation frequency for L5178Y cells was evaluated at dose 0.005 mg/mL in light condition (expt-II),Other,2157014.0,
321,107803,3,4,,103166066,2179,Unspecified,,,,,Relative mutation induction for L5178Y cells was evaluated at dose 0.005 mg/mL in dark condition (expt-II),Other,2157014.0,
322,107804,3,4,,103166066,2179,Unspecified,,,,,Relative mutation induction for L5178Y cells was evaluated at dose 0.005 mg/mL in light condition (expt-II),Other,2157014.0,
323,107805,3,4,,103166066,2179,Unspecified,,,,,Relative toxicity against mammalian L5178Y cells at dose 0.005 mg/mL in dark condition (expt-II),Other,2157014.0,
324,107806,3,4,,103166066,2179,Unspecified,,,,,Relative toxicity against mammalian L5178Y cells at dose 0.005 mg/mL in light condition (expt-II),Other,2157014.0,
325,107807,3,4,,103166066,2179,Unspecified,,,,,Viability of L5178Y cells was evaluated at dose 0.005 mg/mL in dark condition (expt-II),Other,2157014.0,
326,107808,3,4,,103166066,2179,Unspecified,,,,,Viability of L5178Y cells was evaluated at dose 0.005 mg/mL in light condition (expt-II),Other,2157014.0,
327,108702,3,3,,103166066,2179,Unspecified,,,,,"The compound (5 mg/kg, ip) was tested for change in average weight of BDF2 mice bearing B-16 melanoma",Other,7650675.0,
328,108703,3,3,,103166066,2179,Unspecified,,,,,"The compound (5 mg/kg, ip) was tested for change in average weight of BDF2 mice bearing E0771 mammary adenocarcinoma",Other,7650675.0,
329,108704,3,3,,103166066,2179,Unspecified,,,,,"The compound (5 mg/kg, ip) was tested for change in average weight of BDF2 mice bearing Lewis lung carcinoma",Other,7650675.0,
330,110718,6,1,,103166066,2179,Unspecified,,,,,In vitro anticancer activity against B6D2F-1 mice bearing P388 leukemia measured by the Average survival time(day+/-SD) at an intravenous dose of 18(mg/kg).,Other,10579838.0,
331,110723,6,1,,103166066,2179,Unspecified,,,,,In vitro anticancer activity against B6D2F-1 mice bearing P388 leukemia measured by the average survival time(day+/-SD) at an intravenous dose of 8(mg/kg)..,Other,10579838.0,
332,110725,6,1,,103166066,2179,Unspecified,,,,,In vitro anticancer activity against B6D2F-1 mice bearing P388 leukemia measured by the Average survival time(day+/-SD) at an intravenous dose of 12(mg/kg).,Other,10579838.0,
333,110795,3,3,,103166066,2179,Unspecified,,,,,Number of mice(with Colon 38 tumors) cured after treatment of 13.3 mg/kg/day dose given as 3 times in a day for 4 days out of 5 mice,Other,12620081.0,
334,111055,3,4,,103166066,2179,Unspecified,,,,,In vitro anticancer activity against B6D2F-1 mice bearing P388 leukemia measured by the average weight change(g) after day 1 at an intravenous dose of 12(mg/kg).,Other,10579838.0,
335,111064,3,4,,103166066,2179,Unspecified,,,,,In vitro anticancer activity against B6D2F-1 mice bearing P388 leukemia measured by the average weight change(g) after day 1 at an intravenous dose of 8(mg/kg).,Other,10579838.0,
336,111065,3,4,,103166066,2179,Unspecified,,,,,In vitro anticancer activity against B6D2F-1 mice bearing P388 leukemia measured by the average weight change(g) after day 11 at an intravenous dose of 12(mg/kg).,Other,10579838.0,
337,111073,3,4,,103166066,2179,Unspecified,,,,,In vitro anticancer activity against B6D2F-1 mice bearing P388 leukemia measured by the average weight change(g) after day 11 at an intravenous dose of 8(mg/kg).,Other,10579838.0,
338,111075,3,4,,103166066,2179,Unspecified,,,,,In vitro anticancer activity against B6D2F-1 mice bearing P388 leukemia measured by the average weight change(g) after day 7 at an intravenous dose of 12(mg/kg).,Other,10579838.0,
339,111209,3,4,,103166066,2179,Unspecified,,,,,In vitro anticancer activity against B6D2F-1 mice bearing P388 leukemia measured by the average weight change(g) after day 7 at an intravenous dose of 18(mg/kg).,Other,10579838.0,
340,111215,3,4,,103166066,2179,Unspecified,,,,,In vitro anticancer activity against B6D2F-1 mice bearing P388 leukemia measured by the average weight change(g) after day 7 at an intravenous dose of 8(mg/kg).,Other,10579838.0,
341,111216,3,4,,103166066,2179,Unspecified,,,,,In vitro anticancer activity against B6D2F-1 mice bearing P388 leukemia measured by the average weight change(g) after day 9 at an intravenous dose of 12(mg/kg).,Other,10579838.0,
342,111220,3,4,,103166066,2179,Unspecified,,,,,In vitro anticancer activity against B6D2F-1 mice bearing P388 leukemia measured by the average weight change(g) after day 9 at an intravenous dose of 8(mg/kg).,Other,10579838.0,
343,111378,3,4,,103166066,2179,Unspecified,,,,,In vitro anticancer activity against B6D2F-1 mice bearing P388 leukemia measured by the average weight change(g) after day 1 at an intravenous dose of 18(mg/kg).,Other,10579838.0,
344,114262,6,1,,103166066,2179,Unspecified,,,,,In vivo antitumor activity against subcutaneous Colon 38 tumors in mice determined as delay in growth after 13.3 mg/kg/day dose given as 3 times in a day for 4 days,Other,12620081.0,
345,114985,2,4,,103166066,2179,Unspecified,,,,,Compound was evaluated for murine antitumor activity versus Panc 03 expressed as maximum tolerated total dose upon intravenous administration,Other,,
346,115137,2,5,,103166066,2179,Unspecified,,,,,In vivo antitumor activity was measured as maximum tolerated dose in BDF1 male mice implanted with murine pancreatic adenocarcinoma (Panc 03) at dose schedule qd 4-9 administered sc,Other,,
347,116327,3,4,,103166066,2179,Unspecified,,,,,In vitro anticancer activity against B6D2F-1 mice bearing P388 leukemia measured by the increase in lifespan(%) at an intravenous dose of 12(mg/kg).,Other,10579838.0,
348,116329,3,4,,103166066,2179,Unspecified,,,,,In vitro anticancer activity against B6D2F-1 mice bearing P388 leukemia measured by the increase in lifespan(%) at an intravenous dose of 18(mg/kg).,Other,10579838.0,
349,116332,3,4,,103166066,2179,Unspecified,,,,,In vitro anticancer activity against B6D2F-1 mice bearing P388 leukemia measured by the increase in lifespan(%) at an intravenous dose of 8(mg/kg)..,Other,10579838.0,
350,116537,2,4,,103166066,2179,Unspecified,,,,,Compound was evaluated for murine antitumor activity versus Panc 03 expressed as log10 cell kill of tumor bearing mice,Other,,
351,117263,2,4,,103166066,2179,Unspecified,,,,,Compound was evaluated for murine antitumor activity versus Panc 03 expressed as long term cures,Other,,
352,117342,5,2,,103166066,2179,Unspecified,,,,,Percentage increase in life span of drug-treated tumor bearing controls was determined,Other,6546591.0,
353,119953,3,5,,103166066,2179,Unspecified,,,,,Dose of drug given intraperitoneally on a qd 1-5 schedule that provides the highest ILS value in mice bearing 10E6 ip inoculated L1210 leukemia cells,Other,6546591.0,
354,120024,4,3,,103166066,2179,Unspecified,,,,,Average tumor volume of the B-16 melanoma,Other,7650675.0,
355,120026,4,3,,103166066,2179,Unspecified,,,,,"Average tumor volume of the E0771 mammary adenocarcinoma,",Other,7650675.0,
356,120027,4,3,,103166066,2179,Unspecified,,,,,Average tumor volume of the Lewis lung carcinoma,Other,7650675.0,
357,120678,2,4,,103166066,2179,Unspecified,,,,,Compound was evaluated for murine antitumor activity versus Panc 03,Other,,
358,121081,2,4,,103166066,2179,Unspecified,,,,,Tested for tumor growth inhibition in mice,Other,,
359,122429,2,5,,103166066,2179,Unspecified,,,,,In vivo antitumor activity was measured as tumor growth inhibition in BDF1 male mice implanted with murine pancreatic adenocarcinoma (Panc 03) at dose schedule qd 4-9 administered sc,Other,,
360,123409,3,4,,103166066,2179,Unspecified,,,,,In vitro anticancer activity against 5 B6D2F-1 mice bearing P388 leukemia measured by the toxicity death at an intravenous dose of 18(mg/kg).,Other,10579838.0,
361,124470,4,3,,103166066,2179,Unspecified,,,,,In vitro anticancer activity against B6D2F-1 mice bearing P388 leukemia measured by the toxicity death at an intravenous dose of 8(mg/kg)..,Other,10579838.0,
362,124471,4,3,,103166066,2179,Unspecified,,,,,In vitro anticancer activity against B6D2F-1 mice bearing P388 leukemia measured by the toxicity death at an intravenous dose of 12(mg/kg).,Other,10579838.0,
363,130488,3,5,,103166066,2179,Unspecified,,,,,% increase in life span of treated mice over control groups injected with P388 cells alone,Other,6688829.0,
364,130507,3,4,,103166066,2179,Inactive,,,,,Percent increase in life span of the drug treated tumor bearing animals vs nontreated tumor bearing controls was determined against P388/ADR cells;NA= not active,Other,3625706.0,
365,131484,3,5,,103166066,2179,Unspecified,,,,,In vivo increased lifespan in mice implanted intraperitoneally with wild type P388 murine leukemia cell line at the optimal dose of 13.3 mg/kg/day,Other,2153829.0,
366,133759,2,4,,103166066,2179,Unspecified,,,,,In vivo antitumor activity was measured as the maximum dose tolerated by murine when administered intravenously,Other,,
367,133779,3,3,,103166066,2179,Unspecified,,,,,Maximum tolerated dose administarted iv (mg/kg) to mice,Other,9733489.0,
368,134219,3,3,,103166066,2179,Unspecified,,,,,"The log cell kill of tumor-bearing mice, based on tumor growth delay.",Other,9733489.0,
369,134223,3,3,,103166066,2179,Unspecified,,,,,LD10 in mice,Other,6894620.0,
370,134224,3,5,,103166066,2179,Unspecified,,,,,"In vivo toxicity (qd 1-5), determined using the intraperitoneal implantation of L1210 leukemia cells in mice",Other,6988589.0,
371,134904,3,3,,103166066,2179,Unspecified,,,,,The long term cures (LTC) value is the number of mice in a group with no palpable tumor.,Other,9733489.0,
372,135602,3,3,,103166066,2179,Unspecified,,,,,Molar dose providing 40 percent increase in the life span of leukemic mice,Other,6894620.0,
373,135921,3,3,,103166066,2179,Unspecified,,,,,"compound was tested for murine tumor growth inhibition,T/C value (total/control) in mice.",Other,9733489.0,
374,139092,3,4,,103166066,2179,Unspecified,,,,,Drug dose in (mg/kg)/day to provide an increase in life span of 40% was determined,Other,6988589.0,
375,139101,3,4,,103166066,2179,Unspecified,,,,,Percent increase in life span in L1210 assay at the LD10 dose,Other,6988589.0,
376,143042,6,2,,103166066,2179,Active,,,0.06,IC50,Inhibitory activity against NCI-H460 cell line using MTT assay,Confirmatory,10780913.0,
377,143043,6,2,,103166066,2179,Active,,,0.06,IC50,Inhibitory activity against NCI-H460 cell line using MTT assay(Wild type p53),Confirmatory,10780913.0,
378,143360,6,2,,103166066,2179,Active,,,0.07,IC50,Inhibitory activity against NCI-H647 cell line using MTT assay(mutant p53),Confirmatory,10780913.0,
379,144936,6,2,,103166066,2179,Active,,,1.01,IC50,Inhibitory activity against NCI-H226 cell line using MTT assay(mutant p53),Confirmatory,10780913.0,
380,145200,6,2,,103166066,2179,Active,,,0.21,IC50,Inhibitory activity against NCI-H322 cell line using MTT assay(mutant p53),Confirmatory,10780913.0,
381,145206,6,2,,103166066,2179,Active,,,0.15,IC50,Inhibitory activity against NCI-H358 cell line using MTT assay(mutant p53),Confirmatory,10780913.0,
382,146876,3,3,,103166066,2179,Unspecified,,,,,Ability to block cleavage of GCC/GGC site in NaeI enzyme with the test compound/DNA ratio 1(no. of sites=4); - = no activation,Other,2157014.0,
383,146877,3,3,,103166066,2179,Unspecified,,,,,Ability to block cleavage of GCC/GGC site in NaeI enzyme with the test compound/DNA ratio 1:8(no. of sites=4); - = no activation,Other,2157014.0,
384,146878,3,3,,103166066,2179,Unspecified,,,,,Ability to block cleavage of GCC/GGC site in NaeI enzyme with the test compound/DNA ratio 4(no. of sites=4); - = no activation,Other,2157014.0,
385,147016,3,3,,103166066,2179,Unspecified,,,,,Ability to block cleavage of CC/CGGG site in NciI enzyme with the test compound/DNA ratio 1(no. of sites=10); - = no activation,Other,2157014.0,
386,147017,3,3,,103166066,2179,Unspecified,,,,,Ability to block cleavage of CC/CGGG site in NciI enzyme with the test compound/DNA ratio 1:8(no. of sites=10); - = no activation,Other,2157014.0,
387,147018,3,3,,103166066,2179,Unspecified,,,,,Ability to block cleavage of CC/CGGG site in NciI enzyme with the test compound/DNA ratio 4(no. of sites=10); - = no activation,Other,2157014.0,
388,150213,3,5,,103166066,2179,Unspecified,,,,,In vivo activity against P388 leukemia cells,Other,3560159.0,
389,150215,3,4,,103166066,2179,Unspecified,,,,,In vivo dose of drug needed for a percentage increase of 50% in life span of tumor-bearing mice compared to untreated controls after inoculation of 10e6 P388 leukemia cells,Other,6747989.0,
390,150517,6,3,,103166066,2179,Active,,,0.15,IC50,In Vitro Cytotoxicity was measured by quantifying clonogenic survival in soft agar following a 1 hr transient exposure of P388 mouse leukemia cells to compound,Confirmatory,,
391,150522,6,2,,103166066,2179,Active,,,0.012,IC50,In vitro cell growth inhibitory activity against wild type P388 murine leukemia cell line (P388/W),Confirmatory,2153829.0,
392,150524,6,2,,103166066,2179,Active,,,0.89,IC50,In vitro cell growth inhibitory activity was determined against amsacrine-resistant P388 cell line (P388/A).,Confirmatory,2153829.0,
393,150529,6,3,,103166066,2179,Active,,,0.15,IC50,In vitro cytotoxicity against P388 mouse leukemia cells,Confirmatory,,
394,150539,6,3,,103166066,2179,Active,,,0.15,IC50,In vitro cytotoxicity was evaluated following 1 hour transient exposure of P388 mouse leukemia cells to the compound,Confirmatory,,
395,150540,6,2,,103166066,2179,Active,,,0.15,IC50,In vitro cytotoxicity measured by quantifying clonogenic survival in soft agar following a 1-hour transient exposure of p388 mouse leukemia cells.,Confirmatory,9733489.0,
396,150659,4,4,,103166066,2179,Active,,,0.02,IC50,Inhibitory activity against P388 murine leukemia cells,Confirmatory,11384245.0,
397,150664,4,4,,103166066,2179,Active,,,0.02,IC50,Inhibitory activity against Murine p38 leukemia,Confirmatory,10395479.0,
398,150670,4,5,,103166066,2179,Active,,,0.02,IC50,Inhibitory concentration to reduce cell number to 50% of Murine P388 leukemia cell culture,Confirmatory,9207945.0,
399,150673,4,4,,103166066,2179,Active,,,0.02,IC50,Inhibitory concentration required to reduce murine p388 leukemia cell number to 50% of control cultures,Confirmatory,9191970.0,
400,150694,5,1,,103166066,2179,Active,,,0.03,ID50,Concentration for inhibiting the growth of P-388 cells by 50% over 3 days was determined,Confirmatory,7143362.0,
401,152520,3,5,,103166066,2179,Unspecified,,,,,In vivo tumor cell selectivity (ILSmax values)for percentage increase in life span of treated animals over that of P388 tumor bearing untreated control animals,Other,6747989.0,
402,152553,3,5,,103166066,2179,Unspecified,,,,,In vivo for antitumor activity against P388 leukemia,Other,3755758.0,
403,152668,3,5,,103166066,2179,Unspecified,,,,,In vivo inhibition of P388 in mice for optimal (highest nonacutely toxic) dose (OD),Other,6747989.0,
404,152866,3,5,,103166066,2179,Unspecified,,,,,"Percent increase in the life span of treated mice over a group of control mice injected with p388 tumor alone when administered intraperitoneally (9) as a solution in 0.1 mL of 30%,v/v, ethanol/water",Other,6688830.0,
405,152882,3,4,,103166066,2179,Unspecified,,,,,Percent increase in life span of the drug-treated tumor-bearing animals vs nontreated tumor-bearing controls with P388 leukemia cells.,Other,3625706.0,
406,152884,3,6,,103166066,2179,Unspecified,,,,,In vivo for antitumor activity against P388 leukemia,Other,3755758.0,
407,152987,3,5,,103166066,2179,Unspecified,,,,,Ratio of IC50 value of P388/A and P388/W cell lines,Other,2153829.0,
408,153024,3,5,,103166066,2179,Unspecified,,,,,In vivo for antitumor activity against P388 leukemia.,Other,3755758.0,
409,153028,3,6,,103166066,2179,Unspecified,,,,,Optimal dose required to inhibit the P388 intraperitoneal administration.,Other,3625706.0,
410,153029,3,6,,103166066,2179,Unspecified,,,,,In vivo for optimal dose per day for antitumor activity in P388 cells,Other,6688829.0,
411,153434,3,4,,103166066,2179,Unspecified,,,,,"In vivo antitumor activity in mice bearing P388 leukemia cells at an optimal dose of 13.3 mg/kg given on days 1,5,9.",Other,6546590.0,
412,153537,3,5,,103166066,2179,Unspecified,,,,,Optimal dose required to inhibit the P388/ADR cells in vivo after intraperitoneal administration.,Other,3625706.0,
413,153557,3,4,,103166066,2179,Unspecified,,,,,"In vivo antitumor activity in mice bearing P388 leukemia cells at an optimal dose of 65 mg/kg given on days 1,5,9.",Other,6546590.0,
414,153877,3,4,,103166066,2179,Unspecified,,,,,Percentage increase in life span was measured for P-388 cells in culture after intraperitoneal administration of a dose of 13.3 mg/kg,Other,7143362.0,
415,154021,3,5,,103166066,2179,Unspecified,,,,,In vivo antitumor activity against P388 cells expressed as percent increase in lifespan at an optimal dose of 13.3 mg/kg/day ip,Other,3560159.0,
416,158039,6,2,,103166066,2179,Active,,,0.6,IC50,Inhibitory concentration IC50 against Plasmodium falciparum K1 by [3H]hypoxanthine uptake over 24 hr,Confirmatory,8182707.0,
417,162407,3,3,,103166066,2179,Unspecified,,,,,Antitumor activity as association constant for DNA binding to poly (dA.dT),Other,7143362.0,
418,199185,3,3,,103166066,2179,Unspecified,,,,,Ability to block cleavage of G/GNCC site in Restriction endonuclease Sau961 with the test compound/DNA ratio 1:8(no. of sites=15); - = no activation,Other,2157014.0,
419,199186,4,3,,103166066,2179,Unspecified,,,,,Ability to block cleavage of G/GNCC site in Restriction endonuclease Sau961 with the test compound/DNA ratio 4(no. of sites=15); - = no activation,Other,2157014.0,
420,199187,4,3,,103166066,2179,Unspecified,,,,,Ability to block cleavage of G/GNCC site in Restriction endonuclease Sau961 with the test compound/DNA ratio 1(no. of sites=15); - = no activation,Other,2157014.0,
421,199188,4,3,,103166066,2179,Unspecified,,,,,Ability to block cleavage of G/GNCC site in Restriction endonuclease Sau961 with the test compound/DNA ratio 1:8(no. of sites=15); - = no activation,Other,2157014.0,
422,201226,3,4,,103166066,2179,Unspecified,,,,,"The mutagenic effectiveness, lowest molar concentration required for a constant proportion of revertant colonies (chosen as 50 per 10E8 bacteria)",Other,6988589.0,
423,201229,3,4,,103166066,2179,Unspecified,,,,,Concentration of drug needed to kill Salmonella Typhimurium strain TA 1537 grown on histidine-enriched medium,Other,6988589.0,
424,201364,3,4,,103166066,2179,Unspecified,,,,,"Mutagenic efficiency, measured as the concentration providing 50% inhibition of Salmonella Typhimurium strain TA 1537 growth in drug induced-mutant colonies",Other,6988589.0,
425,202679,6,2,,103166066,2179,Active,,,0.06,IC50,"Inhibitory activity against SKBR-3 cell line using MTT assay (ER-amplified erB2,mutant p53)",Confirmatory,10780913.0,
426,208685,6,2,,103166066,2179,Active,,,0.22,IC50,"Inhibitory activity against T47D cell line using MTT assay (ER+,mutant p53)",Confirmatory,10780913.0,
427,210610,3,4,,103166066,2179,Unspecified,,,,,In vitro therapeutic index calculated as the IC50 ratio of Jurkat cells to that of Leishmania major.,Other,9258370.0,
428,210614,4,3,,103166066,2179,Unspecified,,,,,Compound concentration in mole/kg/day lethal to 10% of mice,Other,7069706.0,
429,211122,5,3,,103166066,2179,Active,,,,,Effect of dose dependent inhibition of TOPO II-catalyzed kDNA decatenation in vitro,Other,7525959.0,
430,211282,5,3,,103166066,2179,Unspecified,,,,,"Unwinding of DNA observed in a reaction mixture containing PBR322 DNA dimer, calf thymus DNA topoisomerase II, and the drug; ++ = unwinding was observed at 25 ug/mL",Other,2542558.0,
431,211288,9,5,,103166066,2179,Active,13959709.0,7153.0,0.72,EC50,Inhibition of topoisomerase II purified from HeLa cells,Confirmatory,,
432,211288,9,5,,103166066,2179,Active,20141946.0,7155.0,0.72,EC50,Inhibition of topoisomerase II purified from HeLa cells,Confirmatory,,
433,211290,9,2,,103166066,2179,Active,,,0.72,EC50,Compound was tested for topoisomerase II inhibition in purified HeLa cells by SDS/K+ precipitation method,Confirmatory,,
434,211291,9,3,,103166066,2179,Active,,,0.72,EC50,Inhibitory activity against HeLa cell Topoisomerase II,Confirmatory,,
435,211292,9,1,,103166066,2179,Active,,,0.72,EC50,Tested for inhibition of topoisomerase II isolated from HeLa cells by DNA-cleavage assay,Confirmatory,8410993.0,
436,211293,9,2,,103166066,2179,Active,,,0.72,EC50,Tested for inhibitory activity against Topoisomerase II isolated from HeLa cells by using SDS-K+ precipitation method,Confirmatory,,
437,211310,3,7,,103166066,2179,Unspecified,,,,,Percent of DNA remaining uncut after incubation with Topoisomerase II at 0.1 uM concentration,Other,9871638.0,
438,211311,3,7,,103166066,2179,Unspecified,,,,,Percent of DNA remaining uncut after incubation with Topoisomerase II at 1 uM concentration,Other,9871638.0,
439,211312,3,7,,103166066,2179,Unspecified,,,,,Percent of DNA remaining uncut after incubation with Topoisomerase II at 10 uM concentration,Other,9871638.0,
440,216262,4,5,,103166066,2179,Active,,,1.3539,IC50,Inhibitory concentration required for cytotoxicity in hydroxyrubicin-resistant (WP159/R) cells,Confirmatory,,
441,219914,6,2,,103166066,2179,Active,,,0.24,IC50,Cytotoxicity against CHO cell line xrs6,Confirmatory,7473578.0,
442,220406,6,2,,103166066,2179,Active,,,0.18,IC50,"Inhibitory activity against ZR-75-1 cell line using MTT assay (ER+,pgr+,mutant p53)",Confirmatory,10780913.0,
443,225777,7,1,,103166066,2179,Active,,,,,Inhibitory concentration against ethidium in DNA-binding assay with [poly(dA-dT)]2 (synthetic oligonucleotide),Other,7658436.0,
444,225778,7,1,,103166066,2179,Active,,,,,Inhibitory concentration against ethidium in DNA-binding assay with [poly(dG-dC)]2 (synthetic oligonucleotide),Other,7658436.0,
445,225781,3,4,,103166066,2179,Unspecified,,,,,"Association constant for binding to poly(dA-dT) DNA in 0.01 SHE buffer, measured by ethidium displacement method",Other,2362284.0,
446,225924,3,4,,103166066,2179,Unspecified,,,,,"Association constant for binding to poly(dG-dC) DNA in 0.01 SHE buffer, measured by ethidium displacement method",Other,2362284.0,
447,225937,3,3,,103166066,2179,Unspecified,,,,,Log K value for DNA binding to poly[d(A-T)],Other,6688829.0,
448,225938,3,3,,103166066,2179,Unspecified,,,,,Log K value for DNA binding to poly[d(G-C)],Other,6688829.0,
449,226888,3,3,,103166066,2179,Unspecified,,,,,Ratio of inhibitory concentration of Human Jurkat leukemia A (JLA) and Human Jurkat leukemia C (JLC),Other,9207945.0,
450,226889,3,3,,103166066,2179,Unspecified,,,,,Ratio of inhibitory concentration of Human Jurkat leukemia D (JLD) and Human Jurkat leukemia C (JLC),Other,9207945.0,
451,227078,3,4,,103166066,2179,Unspecified,,,,,Ratio of IC50 against Jurkat human leukemia amsacrine-resistant cells (JLA) to Jurkat human leukemia cells (JLC),Other,11384245.0,
452,227079,3,4,,103166066,2179,Unspecified,,,,,Ratio of IC50 against Jurkat human leukemia doxorubicin-resistant cells (JLD) to Jurkat human leukemia cells (JLC),Other,11384245.0,
453,227361,3,3,,103166066,2179,Unspecified,,,,,Compound was tested for topoisomerase mediated cleavage of DNA; Each + indicates a 2 to 4 fold increase,Other,7241506.0,
454,227751,5,2,,103166066,2179,Inconclusive,,,,,Concentration required to reduce ethidium bromide fluorescence to 50% of control in presence of calf thymus DNA; ND is Not Determined.,Other,7525959.0,
455,228429,9,3,,103166066,2179,Active,,,0.72,EC50,Inhibitory activity in a cell-free assay of DNA cleavage mediated by purified HeLa cell topoisomerase II.,Confirmatory,,
456,229284,3,4,,103166066,2179,Unspecified,,,,,Ratio of IC50 of HCT-8 to IC50 of L1210 cell lines,Other,3560159.0,
457,229289,3,4,,103166066,2179,Unspecified,,,,,"Ratio of IC50 of Jurkat leukemia amsacrine (JLA) to the IC50 of Jurkat leukemia (JLC sensitive, wild type)",Other,9191970.0,
458,229325,3,4,,103166066,2179,Unspecified,,,,,"Ratio of IC50 of mutant Jurkat leukemia (JLD) to the IC50 of Jurkat leukemia (JLC sensitive, wild type)",Other,9191970.0,
459,229741,3,3,,103166066,2179,Unspecified,,,,,Hypersensitivity factor (HF) of IC50 (AA8) / IC50 (EM-9) of compound for repair deffective mutants,Other,2909741.0,
460,229742,3,3,,103166066,2179,Unspecified,,,,,Hypersensitivity factor (HF) of IC50 (AA8) / IC50 (UV-4) of compound for repair deffective mutants,Other,2909741.0,
461,229743,3,3,,103166066,2179,Unspecified,,,,,Hypersensitivity factor (HF) of IC50 (AA8) / IC50 (UV-5) of compound for repair deffective mutants,Other,2909741.0,
462,231477,3,4,,103166066,2179,Unspecified,,,,,Ratio between IC50 value of DOX/R and WP159/R was determined,Other,,
463,232294,3,3,,103166066,2179,Unspecified,,,,,Differential cytotoxicity was determined from the ratio between BR1(IC50) and xrs-6 (IC50),Other,7525959.0,
464,232336,3,3,,103166066,2179,Unspecified,,,,,Ratio of BR1 IC50 to xrs-6 IC50,Other,7473578.0,
465,232616,3,5,,103166066,2179,Unspecified,,,,,Ratio of IC50 against murine leukemia cells (L1210) to that of IC50 against colon tumor cells (HCT-8),Other,3755758.0,
466,234396,3,4,,103166066,2179,Unspecified,,,,,Ratio of inhibitory activity against amsacrine resistant jurkat cells to inhibitory activity against wild type human jurkat cells,Other,10395479.0,
467,234397,3,4,,103166066,2179,Unspecified,,,,,Ratio of inhibitory activity against doxorubicin resistant jurkat cells to inhibitory activity against wild type human jurkat cells,Other,10395479.0,
468,235013,3,4,,103166066,2179,Unspecified,,,,,In vitro therapeutic index value is the ratio between IC50 values of [J] and [P],Other,8182707.0,
469,238250,6,6,,103166066,2179,Active,,,7.5,Ki,Binding affinity for cytochrome P450 2D6,Confirmatory,15481972.0,
470,240619,6,6,,103166066,2179,Active,,,10.5,IC50,Inhibitory concentration against cytochrome P450 2D6,Confirmatory,15481972.0,
471,302338,3,9,,103166066,2179,Active,13959709.0,7153.0,,,Inhibition of human recombinant topoisomerase 2-mediated relaxation of supercoiled plasmid pBR322 DNA at 8 uM,Other,17911018.0,
472,307098,6,2,,103166066,2179,Active,,,0.7,IC50,Cytotoxicity against human HCT116 cells by XTT assay,Confirmatory,17368022.0,
473,307099,6,2,,103166066,2179,Active,,,21.7,IC50,Cytotoxicity against human MCF7 cells by XTT assay,Confirmatory,17368022.0,
474,307100,6,3,,103166066,2179,Active,,,8.5,IC50,Cytotoxicity against human MDA-MB468 cells by XTT assay,Confirmatory,17368022.0,
475,312292,6,2,,103166066,2179,Active,,,0.023,IC50,Cytotoxicity against human K562 cells after 5 days by XTT assay,Confirmatory,18076140.0,
476,316496,3,4,,103166066,2179,Unspecified,,,,,Stability of F21T DNA quadruplex sequence d[G3(T2AG3)3] assessed as thermal denaturation by FRET analysis,Other,18247546.0,
477,317174,6,2,,103166066,2179,Active,,,0.012,IC50,Antiproliferative activity against human HeLa cells after 72 hrs by trypan blue test,Confirmatory,18077173.0,
478,317175,6,2,,103166066,2179,Active,,,0.0051,IC50,Antiproliferative activity against human HL60 cells after 72 hrs by trypan blue test,Confirmatory,18077173.0,
479,320267,6,2,,103166066,2179,Active,,,9.5,IC50,Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay,Confirmatory,18035542.0,
480,320268,6,3,,103166066,2179,Active,,,8.8,IC50,Antiproliferative activity against human C33 cells after 72 hrs by MTT assay,Confirmatory,18035542.0,
481,320269,6,2,,103166066,2179,Active,,,27.7,IC50,Antiproliferative activity against human SW480 cells after 72 hrs by MTT assay,Confirmatory,18035542.0,
482,320270,6,2,,103166066,2179,Active,,,16.7,IC50,Antiproliferative activity against human SW620 cells after 72 hrs by MTT assay,Confirmatory,18035542.0,
483,320271,6,2,,103166066,2179,Active,,,19.9,IC50,Antiproliferative activity against human K562 cells after 72 hrs by MTT assay,Confirmatory,18035542.0,
484,326626,6,2,,103166066,2179,Active,,,21.7,IC50,Cytotoxicity against human MCF7 cells by XTT assay,Confirmatory,18093835.0,
485,347893,6,2,,103166066,2179,Active,,,5.89,IC50,Cytotoxicity against human A431 cells after 72 hrs by MTT assay,Confirmatory,19101158.0,
486,347894,6,2,,103166066,2179,Active,,,3.52,IC50,Cytotoxicity against human A549 cells after 72 hrs by MTT assay,Confirmatory,19101158.0,
487,347895,6,2,,103166066,2179,Active,,,4.31,IC50,Cytotoxicity against human 2008 cells after 72 hrs by MTT assay,Confirmatory,19101158.0,
488,347896,6,2,,103166066,2179,Active,,,5.13,IC50,Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay,Confirmatory,19101158.0,
489,347897,6,2,,103166066,2179,Active,,,1.15,IC50,Cytotoxicity against human HL60 cells after 72 hrs by MTT assay,Confirmatory,19101158.0,
490,347898,3,3,,103166066,2179,Active,,,,,Binding affinity to salmon testes DNA assessed as negative dichroic signal by linear dichroism experiment,Other,19101158.0,
491,351110,6,2,,103166066,2179,Active,,,9.5,IC50,Cytotoxicity against human HeLa cells after 72 hrs by MTT assay,Confirmatory,19364657.0,
492,351111,6,2,,103166066,2179,Active,,,27.7,IC50,Cytotoxicity against human SW480 cells after 72 hrs by MTT assay,Confirmatory,19364657.0,
493,351112,6,2,,103166066,2179,Active,,,16.7,IC50,Cytotoxicity against human SW620 cells after 72 hrs by MTT assay,Confirmatory,19364657.0,
494,351113,6,2,,103166066,2179,Active,,,19.9,IC50,Cytotoxicity against human K562 cells after 72 hrs by MTT assay,Confirmatory,19364657.0,
495,351114,9,5,,103166066,2179,Active,13959709.0,7153.0,9.94,IC50,Inhibition of human DNA topoisomerase 2-mediated Crithidia fasciculata kDNA decatenation using ethidium bromide staining by agarose gel electrophoresis,Confirmatory,19364657.0,
496,355286,3,3,,103166066,2179,Unspecified,,,,,DNA damaging activity against wild-type Saccharomyces cerevisiae assessed as drug level required to produce 12 mm zone of inhibition assessed per 100 uL after 48 hrs,Other,9358640.0,
497,355287,3,3,,103166066,2179,Unspecified,,,,,DNA damaging activity against RAD52 DNA repair gene deficient Saccharomyces cerevisiae mutant assessed as drug level required to produce 12 mm zone of inhibition assessed per 100 uL after 48 hrs,Other,9358640.0,
498,355288,3,3,,103166066,2179,Unspecified,,,,,DNA damaging activity against RAD52 DNA repair gene/topoisomerase 1 deficient Saccharomyces cerevisiae GAL4:RAD52 mutant assessed as drug level required to produce 12 mm zone of inhibition assessed per 100 uL in glucose medium after 48 hrs,Other,9358640.0,
499,355289,3,3,,103166066,2179,Unspecified,,,,,DNA damaging activity against RAD52 DNA repair gene/topoisomerase 1 deficient Saccharomyces cerevisiae GAL4:RAD52 mutant assessed as drug level required to produce 12 mm zone of inhibition assessed per 100 uL in galactose medium after 48 hrs,Other,9358640.0,
500,355578,9,1,,103166066,2179,Active,,,0.5589999999999999,IC50,Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay,Confirmatory,2778449.0,
501,355579,3,5,,103166066,2179,Inactive,,,,,Antiproliferative activity against human HT-29 cells at 10 ug after 48 hrs by two-layer agar-diffusion method,Other,2778449.0,
502,355580,3,5,,103166066,2179,Inactive,,,,,Antiproliferative activity against human HT-29 cells at 1 ug after 48 hrs by two-layer agar-diffusion method,Other,2778449.0,
503,355581,3,5,,103166066,2179,Inactive,,,,,Antiproliferative activity against human HT-29 cells at 0.1 ug after 48 hrs by two-layer agar-diffusion method,Other,2778449.0,
504,355582,3,5,,103166066,2179,Inactive,,,,,Antiproliferative activity against human HT-29 cells at 0.01 ug after 48 hrs by two-layer agar-diffusion method,Other,2778449.0,
505,355583,9,1,,103166066,2179,Active,,,0.22899999999999998,IC50,Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay,Confirmatory,2778449.0,
506,355584,3,5,,103166066,2179,Unspecified,,,,,Antiproliferative activity against mouse P388 cells at 1 ug after 48 hrs by two-layer agar-diffusion method,Other,2778449.0,
507,355585,3,5,,103166066,2179,Unspecified,,,,,Antiproliferative activity against mouse P388 cells at 0.1 ug after 48 hrs by two-layer agar-diffusion method,Other,2778449.0,
508,355586,3,5,,103166066,2179,Inactive,,,,,Antiproliferative activity against mouse P388 cells at 0.01 ug after 48 hrs by two-layer agar-diffusion method,Other,2778449.0,
509,363203,5,3,,103166066,2179,Active,,,0.22909000000000002,GI50,Antitumor activity against human NCI60 cells after 48 hrs by SRB assay,Confirmatory,18715786.0,
510,365810,6,3,,103166066,2179,Active,,,0.74,IC50,Cytotoxicity against human M4Beu cells by resazurin reduction test,Confirmatory,18656367.0,
511,365811,6,3,,103166066,2179,Active,,,4.2,IC50,Cytotoxicity against human fibroblast cells by resazurin reduction test,Confirmatory,18656367.0,
512,365812,6,2,,103166066,2179,Active,,,0.57,IC50,Cytotoxicity against human DLD1 cells by resazurin reduction test,Confirmatory,18656367.0,
513,365813,6,2,,103166066,2179,Active,,,0.08,IC50,Cytotoxicity against human Jurkat cells by resazurin reduction test,Confirmatory,18656367.0,
514,365814,6,3,,103166066,2179,Active,,,0.08,IC50,Cytotoxicity against mouse B16F0 cells by resazurin reduction test,Confirmatory,18656367.0,
515,365815,6,3,,103166066,2179,Active,,,0.4,IC50,Cytotoxicity against human M4Beu cells by Hoechst test,Confirmatory,18656367.0,
516,365816,6,3,,103166066,2179,Active,,,0.04,IC50,Cytotoxicity against mouse B16F0 cells by Hoechst test,Confirmatory,18656367.0,
517,365817,6,2,,103166066,2179,Active,,,0.08,IC50,Cytotoxicity against human DLD1 cells by Hoechst test,Confirmatory,18656367.0,
518,365818,6,2,,103166066,2179,Active,,,0.02,IC50,Cytotoxicity against human Jurkat cells by Hoechst test,Confirmatory,18656367.0,
519,365819,6,3,,103166066,2179,Active,,,2.0,IC50,Cytotoxicity against human fibroblast cells by Hoechst test,Confirmatory,18656367.0,
520,382900,4,4,,103166066,2179,Active,,,0.13,IC50,Cytotoxicity against human CCRF-CEM cells after 72 hrs,Confirmatory,18329887.0,
521,382901,3,4,,103166066,2179,Unspecified,,,,,Cell cycle arrest in human CCRF-CEM cells assessed as accumulation at G2/M phase at 1 time IC50 after 24 hrs by flow cytometry,Other,18329887.0,
522,383232,3,4,,103166066,2179,Unspecified,,,,,Cell cycle arrest in human OVCAR-3 cells assessed as accumulation at subG0 phase at 16 uM by flow cytometry,Other,17573162.0,
523,383233,3,4,,103166066,2179,Unspecified,,,,,Cell cycle arrest in human OVCAR-3 cells assessed as accumulation at G0/G1 phase at 16 uM by flow cytometry,Other,17573162.0,
524,383234,3,4,,103166066,2179,Unspecified,,,,,Cell cycle arrest in human OVCAR-3 cells assessed as accumulation at S phase at 16 uM by flow cytometry,Other,17573162.0,
525,383235,3,4,,103166066,2179,Unspecified,,,,,Cell cycle arrest in human OVCAR-3 cells assessed as accumulation at G2/M phase at 16 uM by flow cytometry,Other,17573162.0,
526,386536,9,5,,103166066,2179,Active,7531135.0,3757.0,0.21,IC50,Inhibition of human ERG potassium channel,Confirmatory,18243713.0,
527,386623,4,8,,103166066,2179,Unspecified,313104181.0,6580.0,,,Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy,Other,18788725.0,
528,386625,9,5,,103166066,2179,Active,313104181.0,6580.0,5.0,IC50,Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells by confocal microscopy,Confirmatory,18788725.0,
529,396406,6,2,,103166066,2179,Active,,,1.6,GI50,Antiproliferative activity against human HT1080 cells after 48 hrs by SRB assay,Confirmatory,18403058.0,
530,396407,6,2,,103166066,2179,Active,,,16.8,GI50,Antiproliferative activity against human HT-29 cells after 48 hrs by SRB assay,Confirmatory,18403058.0,
531,396408,6,2,,103166066,2179,Active,,,49.6,GI50,Antiproliferative activity against human M21 cells after 48 hrs by SRB assay,Confirmatory,18403058.0,
532,396409,6,2,,103166066,2179,Active,,,5.6,GI50,Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay,Confirmatory,18403058.0,
533,426108,3,3,,103166066,2179,Active,,,,,Binding affinity to salmon testes DNA assessed as occurrence of intercalative molecular complex by linear flow dichroism,Other,19155103.0,
534,426114,3,9,,103166066,2179,Active,13959709.0,7153.0,,,Inhibition of human recombinant topoisomerase 2 assessed as induction of linear pBR322 DNA formation at 15 uM by agarose gel electrophoresis,Other,19155103.0,
535,427933,3,9,,103166066,2179,Active,13959709.0,7153.0,,,Inhibition of human recombinant topoisomerase 2 relaxation activity assessed as supercoiled pBR322 DNA at 8 uM,Other,19725581.0,
536,427938,3,3,,103166066,2179,Active,,,,,Stabilization of supercoiled pBR322 DNA-human recombinant topoisomerase 2 complex assessed as reduction in linear DNA formation at 8 uM,Other,19725581.0,
537,456324,5,2,,103166066,2179,Active,,,0.44,GI50,Growth inhibition of human NCI60 cells,Confirmatory,19944612.0,
538,463106,1,2,,90341308,2179,Inactive,188528692.0,9099.0,,Potency,qHTS Validation Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
539,477295,3,3,,103166066,2179,Unspecified,,,,,"Octanol-water partition coefficient, log P of the compound",Other,20106561.0,
540,485295,1,2,,90341308,2179,Inconclusive,30027657.0,,29.9349,Potency,qHTS Validation Assay for the Inhibitors of DNA Replication in Gram-Positive Bacteria,Confirmatory,,
541,485297,1,1,,90341308,2179,Inactive,4759012.0,9367.0,73.078,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
542,485298,1,1,,90341308,2179,Inconclusive,,,18.3564,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
543,485313,1,2,,90341308,2179,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
544,485342,1,2,,90341308,2179,Inactive,5454140.0,7251.0,,Potency,qHTS Validation Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
545,485345,1,2,,90341308,2179,Inconclusive,,,,Potency,qHTS Validation Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
546,485366,1,2,,90341308,2179,Inactive,4501969.0,154.0,,Potency,qHTS validation assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
547,485368,1,2,,90341308,2179,Inactive,72386991.0,3656265.0,,Potency,qHTS Validation Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
548,487000,3,3,,103166066,2179,Unspecified,,,,,Binding affinity to calf thymus DNA assessed as ratio of final absorbance area to the absorbance at 100 uM after 24 hrs by UV spectrophotometer analysis relative to control,Other,20471844.0,
549,488772,1,1,,90341308,2179,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
550,488773,1,2,,90341308,2179,Inactive,8659577.0,58819.0,18.8876,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
551,488816,1,1,,90341308,2179,Inactive,4758356.0,2237.0,,Potency,qHTS Validation Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1),Confirmatory,,
552,488837,1,1,,90341308,2179,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
553,488949,1,2,,90341308,2179,Inactive,41055989.0,54737.0,,Potency,qHTS Validation Assay for Inhibitors for MPP8 Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
554,488953,1,1,,90341308,2179,Active,187960037.0,10951.0,79.4328,Potency,qHTS Validation Assay for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
555,488978,1,1,,90341308,2179,Inactive,45359078.0,,,Potency,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity: MmCpn Primary Screen,Confirmatory,,
556,488981,1,1,,90341308,2179,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Agonists,Confirmatory,,
557,488982,1,1,,90341308,2179,Inactive,4503383.0,1812.0,0.1636,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Potentiators,Confirmatory,,
558,488983,1,1,,90341308,2179,Active,4503383.0,1812.0,1.122,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Antagonists,Confirmatory,,
559,493106,1,1,,90341308,2179,Inconclusive,116283940.0,79915.0,20.5878,Potency,Validation screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
560,493107,1,1,,90341308,2179,Active,116283940.0,79915.0,14.575,Potency,Validation screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
561,493153,1,1,,90341308,2179,Inconclusive,,4780.0,11.5821,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
562,493153,1,1,,90341308,2179,Inconclusive,224028257.0,4780.0,11.5821,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
563,493164,1,2,,90341308,2179,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
564,493164,1,2,,90341308,2179,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
565,493164,1,2,,90341308,2179,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
566,497321,2,3,,103166066,2179,Active,,,,,Stabilization of supercoiled pBR322 DNA-human recombinant topoisomerase 2 complex assessed as linear DNA formation at 8 uM after 60 mins,Other,20615713.0,
567,504327,1,1,,90341308,2179,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
568,504332,1,1,,90341308,2179,Active,168985070.0,,11.9173,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
569,504536,1,1,,90341308,2179,Inactive,5453898.0,5300.0,,Potency,qHTS Validation Assay to Find Inhibitors of Pin1,Confirmatory,,
570,504547,1,1,,90341308,2179,Inactive,115503961.0,4357161.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
571,504548,1,2,,90341308,2179,Inactive,157877932.0,5655980.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Mutase,Confirmatory,,
572,504810,1,2,,90341308,2179,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
573,504812,1,2,,90341308,2179,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
574,504836,1,2,,90341308,2179,Inactive,168984549.0,,,Potency,Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation,Confirmatory,11836247.0,
575,504845,1,1,,90341308,2179,Inconclusive,86301163.0,5999.0,37.6858,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
576,504847,1,1,,90341308,2179,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
577,504865,1,1,,90341308,2179,Inconclusive,118600387.0,7398.0,0.5623,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
578,538150,1,4,,103166066,2179,Unspecified,,,,,Binding affinity to calf thymus DNA assessed as ratio of final absorbance area to absorbance of compound at 100 uM after 24 hrs by UV spectrophotometer analysis,Other,20846761.0,
579,540209,4,3,,103166066,2179,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,18426954.0,
580,540210,4,3,,103166066,2179,Unspecified,,,,,Clearance in human after iv administration,Other,18426954.0,
581,540211,2,5,,103166066,2179,Unspecified,,,,,Fraction unbound in human after iv administration,Other,18426954.0,
582,540212,4,3,,103166066,2179,Unspecified,,,,,Mean residence time in human after iv administration,Other,18426954.0,
583,540213,4,3,,103166066,2179,Unspecified,,,,,Half life in human after iv administration,Other,18426954.0,
584,540256,1,2,,90341308,2179,Active,,,0.5802,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
585,540276,1,2,,11110803,2179,Active,420597.0,,0.7305,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
586,540276,1,2,,50110958,2179,Active,420597.0,,0.7305,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
587,540276,1,2,,90341308,2179,Active,420597.0,,0.7305,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
588,547838,4,7,,103166066,2179,Active,215273968.0,316.0,3.2,IC50,Inhibition of human aldehyde oxidase,Confirmatory,20853847.0,
589,547840,4,7,,103166066,2179,Active,20978407.0,54349.0,,IC50,Inhibition of rat aldehyde oxidase,Confirmatory,20853847.0,
590,547841,4,2,,103166066,2179,Active,,,7.7,IC50,Inhibition of guinea pig aldehyde oxidase,Confirmatory,20853847.0,
591,547842,4,7,,103166066,2179,Active,20981678.0,100008601.0,,IC50,Inhibition of rabbit aldehyde oxidase,Confirmatory,20853847.0,
592,576612,7,5,,103166066,2179,Active,7531135.0,3757.0,0.20893,IC50,Inhibition of human ERG,Confirmatory,21185626.0,
593,576613,4,2,,103166066,2179,Active,,,0.006,IC50,Growth inhibition in human HL60 cells after 72 hrs by trypan blue assay,Confirmatory,21216603.0,
594,576614,4,2,,103166066,2179,Active,,,0.17,IC50,Growth inhibition in human A431 cells after 72 hrs by trypan blue assay,Confirmatory,21216603.0,
595,576615,4,2,,103166066,2179,Active,,,0.012,IC50,Growth inhibition in human HeLa cells after 72 hrs by trypan blue assay,Confirmatory,21216603.0,
596,576623,2,3,,103166066,2179,Active,,,,,Stabilization of supercoiled pBR322 DNA-human recombinant topoisomerase 2 complex assessed as linear DNA formation at 8 uM after 60 mins,Other,21216603.0,
597,588211,2,3,,103166066,2179,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans",Other,20014752.0,
598,588212,2,3,,103166066,2179,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents",Other,20014752.0,
599,588213,2,3,,103166066,2179,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents",Other,20014752.0,
600,588349,1,1,,90341308,2179,Inconclusive,,,2.8184,Potency,qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay,Confirmatory,,
601,588378,1,1,,90341308,2179,Active,171543895.0,6311.0,0.3548,Potency,qHTS for Inhibitors of ATXN expression: Validation,Confirmatory,,
602,588453,1,1,,90341308,2179,Inactive,8659577.0,58819.0,19.9526,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
603,588456,1,1,,90341308,2179,Inactive,8659577.0,58819.0,31.6228,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
604,588579,1,1,,90341308,2179,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
605,588795,1,1,,90341308,2179,Inconclusive,4758356.0,2237.0,5.9728,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
606,602332,1,1,,90341308,2179,Inactive,168984549.0,,58.4789,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
607,606655,3,3,,103166066,2179,Active,,,0.44,GI50,Anticancer activity against human NCI60 cells,Confirmatory,21599000.0,
608,624146,1,1,,90341308,2179,Active,71051501.0,2744.0,1.0,Potency,qHTS for Inhibitors of Glutaminase (GLS): LOPAC Validation,Confirmatory,,
609,624147,1,1,,90341308,2179,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors: LOPAC Validation,Confirmatory,,
610,624148,1,2,,90341308,2179,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists: LOPAC Validation,Confirmatory,,
611,624149,1,1,,90341308,2179,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators: LOPAC Validation,Confirmatory,,
612,624455,1,1,,90341308,2179,Inactive,299681.0,1812.0,,Potency,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Hit Validation in HTRF,Confirmatory,,
613,625279,1,3,,103166066,2179,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia,Other,22194678.0,
614,625280,1,3,,103166066,2179,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis,Other,22194678.0,
615,625281,1,3,,103166066,2179,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis,Other,22194678.0,
616,625282,1,3,,103166066,2179,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis,Other,22194678.0,
617,625283,1,3,,103166066,2179,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests,Other,22194678.0,
618,625284,1,3,,103166066,2179,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure,Other,22194678.0,
619,625285,1,3,,103166066,2179,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis,Other,22194678.0,
620,625286,1,3,,103166066,2179,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis,Other,22194678.0,
621,625287,1,3,,103166066,2179,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly,Other,22194678.0,
622,625288,1,3,,103166066,2179,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice,Other,22194678.0,
623,625289,1,3,,103166066,2179,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease,Other,22194678.0,
624,625290,1,3,,103166066,2179,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty,Other,22194678.0,
625,625291,1,3,,103166066,2179,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal,Other,22194678.0,
626,625292,1,3,,103166066,2179,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score,Other,22194678.0,
627,651635,1,3,,90341308,2179,Inconclusive,171543895.0,6311.0,19.9526,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
628,652106,1,1,,90341308,2179,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
629,657771,2,2,,103166066,2179,Active,,,1.6,GI50,Cytocidal activity against human HT1080 cells assessed as growth inhibition after 48 hrs by SRB assay,Confirmatory,22503207.0,
630,657772,2,2,,103166066,2179,Active,,,16.8,GI50,Cytocidal activity against human HT-29 cells assessed as growth inhibition after 48 hrs by SRB assay,Confirmatory,22503207.0,
631,657773,2,2,,103166066,2179,Active,,,49.6,GI50,Cytocidal activity against human M21 cells assessed as growth inhibition after 48 hrs by SRB assay,Confirmatory,22503207.0,
632,657774,2,2,,103166066,2179,Active,,,5.6,GI50,Cytocidal activity against human MCF7 cells assessed as growth inhibition after 48 hrs by SRB assay,Confirmatory,22503207.0,
633,665977,2,2,,103166066,2179,Active,,,21.7,IC50,Cytotoxicity against human PBMC after 72 hrs by alamar blue assay,Confirmatory,22546208.0,
634,665978,2,2,,103166066,2179,Active,,,5.8,IC50,Cytotoxicity against chinese hamster V79 cells after 72 hrs by MTT assay,Confirmatory,22546208.0,
635,665979,2,2,,103166066,2179,Inconclusive,,,,IC50,Antiproliferative activity against human MDA-MB-435 cells after 72 hrs by MTT assay,Confirmatory,22546208.0,
636,665980,2,2,,103166066,2179,Active,,,1.4,IC50,Antiproliferative activity against human OVCAR8 cells after 72 hrs by MTT assay,Confirmatory,22546208.0,
637,665981,2,2,,103166066,2179,Inconclusive,,,,IC50,Antiproliferative activity against human UACC62 cells after 72 hrs by MTT assay,Confirmatory,22546208.0,
638,665982,2,2,,103166066,2179,Active,,,0.3,IC50,Antiproliferative activity against human DU145 cells after 72 hrs by MTT assay,Confirmatory,22546208.0,
639,665983,2,2,,103166066,2179,Active,,,0.5,IC50,Antiproliferative activity against human SF295 cells after 72 hrs by MTT assay,Confirmatory,22546208.0,
640,665984,2,2,,103166066,2179,Inconclusive,,,,IC50,Antiproliferative activity against human MX1 cells after 72 hrs by MTT assay,Confirmatory,22546208.0,
641,665985,2,2,,103166066,2179,Active,,,3.3,IC50,Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay,Confirmatory,22546208.0,
642,665986,2,3,,103166066,2179,Inconclusive,,,,IC50,Antiproliferative activity against human Hs578T cells after 72 hrs by MTT assay,Confirmatory,22546208.0,
643,665987,2,2,,103166066,2179,Active,,,1.1,IC50,Antiproliferative activity against human COLO205 cells after 72 hrs by MTT assay,Confirmatory,22546208.0,
644,665988,2,2,,103166066,2179,Inconclusive,,,,IC50,Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay,Confirmatory,22546208.0,
645,665989,2,2,,103166066,2179,Active,,,0.3,IC50,Antiproliferative activity against human HCT15 cells after 72 hrs by MTT assay,Confirmatory,22546208.0,
646,665990,2,2,,103166066,2179,Active,,,0.3,IC50,Antiproliferative activity against human SW620 cells after 72 hrs by MTT assay,Confirmatory,22546208.0,
647,665991,2,2,,103166066,2179,Inconclusive,,,,IC50,Antiproliferative activity against human CEM cells after 72 hrs by MTT assay,Confirmatory,22546208.0,
648,665992,2,2,,103166066,2179,Active,,,0.3,IC50,Antiproliferative activity against human HCT8 cells after 72 hrs by MTT assay,Confirmatory,22546208.0,
649,665993,2,2,,103166066,2179,Active,,,0.08,IC50,Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay,Confirmatory,22546208.0,
650,665994,2,2,,103166066,2179,Inconclusive,,,,IC50,Antiproliferative activity against human K562 cells after 72 hrs by MTT assay,Confirmatory,22546208.0,
651,671588,1,7,,103166066,2179,Active,13959709.0,7153.0,,,Inhibition of human recombinant topoisomerase 2alpha-mediated pBR322 DNA relaxation at 8 uM after 60 mins by agarose gel electrophoretic analysis,Other,22537681.0,
652,671590,1,7,,103166066,2179,Active,13959709.0,7153.0,,,Inhibition of human recombinant topoisomerase 2alpha-mediated pBR322 DNA complex formation at 8 uM after 60 mins by agarose gel electrophoresis,Other,22537681.0,
653,678712,1,8,,103166066,2179,Active,117144.0,1544.0,,,Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins,Other,22931300.0,
654,678713,1,8,,103166066,2179,Active,6686268.0,1559.0,,,Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins,Other,22931300.0,
655,678714,1,8,,103166066,2179,Active,60416369.0,1557.0,,,Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins,Other,22931300.0,
656,678715,1,8,,103166066,2179,Active,84028191.0,1565.0,,,Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins,Other,22931300.0,
657,678716,1,8,,103166066,2179,Active,116241312.0,1576.0,,,Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins,Other,22931300.0,
658,678717,1,8,,103166066,2179,Active,116241312.0,1576.0,,,Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins,Other,22931300.0,
659,678718,1,5,,103166066,2179,Unspecified,,,,,Metabolic stability in human liver microsomes assessed as high signal/noise ratio (S/N of >100) by measuring GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis,Other,22931300.0,
660,678722,1,5,,103166066,2179,Inconclusive,,,,,Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH,Other,22931300.0,
661,680267,1,8,,103166066,2179,Unspecified,238054374.0,5243.0,,,"TP_TRANSPORTER: increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.5 uM, m-Amsacrine: 5 uM) in MDR1-expressing NIH-3T3 cells",Other,14985103.0,
662,683863,1,7,,103166066,2179,Unspecified,13959709.0,7153.0,,,Inhibition of human topoisomerase 2-mediated [3H]TdR-labeled catenated kinetoplast DNA decatenation after 15 to 30 mins by scintillation counting,Other,22944121.0,
663,720538,1,2,,90341308,2179,Inactive,220983390.0,410.0,,Potency,qHTS screen for enhancers of Arylsulfatase A (ASA1): LOPAC Validation Assay,Confirmatory,,
664,720559,1,2,,90341308,2179,Inactive,112927.0,351.0,,Potency,qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: LOPAC Validation Assay,Confirmatory,,
665,720572,1,2,,90341308,2179,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (NLuc Reporter),Confirmatory,,
666,720573,1,2,,90341308,2179,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (FLuc Reporter),Confirmatory,,
667,743205,1,1,,90341308,2179,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
668,743205,1,1,,90341308,2179,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
669,743206,1,1,,90341308,2179,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
670,743206,1,1,,90341308,2179,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
671,743207,1,1,,90341308,2179,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
672,743207,1,1,,90341308,2179,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
673,743244,1,1,,90341308,2179,Inconclusive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
674,774945,1,1,,103166066,2179,Active,,,,,Induction of pHOT1 DNA (unknown origin) intercalating activity assessed as blockade of DNA unwinding at 50 to 500 uM after 30 mins by agarose gel electrophoresis in presence of DNA topoisomerase-1,Other,24013413.0,
675,776102,1,5,,103166066,2179,Unspecified,12644118.0,7150.0,,,Inhibition of human topoisomerase 1-mediated unwinding of pHOT1 plasmid DNA after 30 mins by agarose gel electrophoresis,Other,24090914.0,
676,1079931,1,1,,103166066,2179,Unspecified,,,,,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",Other,15646539.0,
677,1079932,1,1,,103166066,2179,Unspecified,,,,,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",Other,15646539.0,
678,1079933,1,1,,103166066,2179,Unspecified,,,,,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",Other,15646539.0,
679,1079934,1,1,,103166066,2179,Unspecified,,,,,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",Other,15646539.0,
680,1079935,1,1,,103166066,2179,Unspecified,,,,,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",Other,15646539.0,
681,1079936,1,1,,103166066,2179,Unspecified,,,,,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",Other,15646539.0,
682,1079937,1,1,,103166066,2179,Unspecified,,,,,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",Other,15646539.0,
683,1079938,1,1,,103166066,2179,Unspecified,,,,,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",Other,15646539.0,
684,1079939,1,1,,103166066,2179,Unspecified,,,,,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",Other,15646539.0,
685,1079940,1,1,,103166066,2179,Unspecified,,,,,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",Other,15646539.0,
686,1079941,1,1,,103166066,2179,Unspecified,,,,,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",Other,15646539.0,
687,1079942,1,1,,103166066,2179,Unspecified,,,,,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",Other,15646539.0,
688,1079943,1,1,,103166066,2179,Unspecified,,,,,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",Other,15646539.0,
689,1079944,1,1,,103166066,2179,Unspecified,,,,,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",Other,15646539.0,
690,1079945,1,1,,103166066,2179,Unspecified,,,,,Animal toxicity known. [column 'TOXIC' in source],Other,15646539.0,
691,1079946,1,1,,103166066,2179,Unspecified,,,,,Presence of at least one case with successful reintroduction. [column 'REINT' in source],Other,15646539.0,
692,1079947,1,1,,103166066,2179,Unspecified,,,,,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],Other,15646539.0,
693,1079948,1,1,,103166066,2179,Unspecified,,,,,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",Other,15646539.0,
694,1079949,1,1,,103166066,2179,Unspecified,,,,,Proposed mechanism(s) of liver damage. [column 'MEC' in source],Other,15646539.0,
695,1133942,1,1,,103166066,2179,Unspecified,,,,,"Lipophilic-hydrophilic balance, Rm of the compound by reversed-phase partition chromatography",Other,850238.0,
696,1133944,1,1,,103166066,2179,Unspecified,,,,,Toxicity in ip dosed mouse assessed as optimum dose that providing maximum increase in life span administered qd for 1 to 5 days,Other,850238.0,
697,1133945,1,1,,103166066,2179,Unspecified,,,,,Antitumor activity against mouse L1210 cells subcutaneously xenografted in ip dosed C3H/DBA2 F1 hybrid mouse assessed as increase in host lifespan administered daily for 5 days starting 24 hrs post-tumor implantation,Other,850238.0,
698,1133946,1,1,,103166066,2179,Unspecified,,,,,Antitumor activity against mouse L1210 cells intraperitoneally xenografted in ip dosed C3H/DBA2 F1 hybrid mouse assessed as increase in host lifespan administered daily for 5 days starting 24 hrs post-tumor implantation,Other,850238.0,
699,1145938,1,1,,103166066,2179,Unspecified,,,,,Cytotoxicity against mouse L1210 cells assessed as growth inhibition at 100 ug/ml after 24 hrs,Other,184284.0,
700,1145939,1,1,,103166066,2179,Unspecified,,,,,Cytotoxicity against mouse L1210 cells assessed as growth inhibition at 100 ug/ml after 48 hrs,Other,184284.0,
701,1145940,1,1,,103166066,2179,Unspecified,,,,,Cytotoxicity against mouse L1210 cells assessed as growth inhibition at 10 ug/ml after 24 hrs,Other,184284.0,
702,1145941,1,1,,103166066,2179,Unspecified,,,,,Cytotoxicity against mouse L1210 cells assessed as growth inhibition at 10 ug/ml after 48 hrs,Other,184284.0,
703,1145942,1,1,,103166066,2179,Unspecified,,,,,Cytotoxicity against mouse L1210 cells assessed as growth inhibition at 1 ug/ml after 24 hrs,Other,184284.0,
704,1145943,1,1,,103166066,2179,Unspecified,,,,,Cytotoxicity against mouse L1210 cells assessed as growth inhibition at 1 ug/ml after 48 hrs,Other,184284.0,
705,1145944,1,1,,103166066,2179,Unspecified,,,,,Cytotoxicity against mouse L1210 cells assessed as growth inhibition at 0.1 ug/ml after 24 hrs,Other,184284.0,
706,1145945,1,1,,103166066,2179,Unspecified,,,,,Cytotoxicity against mouse L1210 cells assessed as growth inhibition at 0.1 ug/ml after 48 hrs,Other,184284.0,
707,1145946,1,1,,103166066,2179,Unspecified,,,,,Cytotoxicity against mouse L1210 cells assessed as growth inhibition at 0.01 ug/ml after 24 hrs,Other,184284.0,
708,1145947,1,1,,103166066,2179,Unspecified,,,,,Cytotoxicity against mouse L1210 cells assessed as growth inhibition at 0.01 ug/ml after 48 hrs,Other,184284.0,
709,1148372,1,1,,103166066,2179,Unspecified,,,,,"Dissociation constant, basic pKa of the compound by UV spectrophotometry",Other,619148.0,
710,1148373,1,1,,103166066,2179,Unspecified,,,,,"Lipopholic-hydrophilic balance, Rm of the compound by reversed-phase chromatography",Other,619148.0,
711,1148374,1,1,,103166066,2179,Unspecified,,,,,Antitumor activity against mouse L1210 cells transfected in ip dosed C3H/DBA2 F1 mouse qd administered for 5 days,Other,619148.0,
712,1148375,1,1,,103166066,2179,Unspecified,,,,,Antitumor activity against mouse L1210 cells transfected in C3H/DBA2 F1 mouse assessed as increase in life span at optimum dose administered ip qd for 5 days relative to control,Other,619148.0,
713,1148471,1,1,,103166066,2179,Active,,,,,Displacement of ethidium bromide from calf thymus DNA by spectrofluorometric analysis,Other,671464.0,
714,1148472,1,1,,103166066,2179,Unspecified,,,,,Induction of bacteriophage PM2 closed circular DNA unwinding assessed as drug per nucleic acid phosphate ratio at equivalence by viscometric analysis,Other,671464.0,
715,1148474,1,1,,103166066,2179,Unspecified,,,,,Antitumor activity against mouse L1210 cells allografted in ip dosed BDF1 mouse at optimum dose administered qd for 5 days relative to control,Other,671464.0,
716,1148475,1,1,,103166066,2179,Unspecified,,,,,Toxicity in ip dosed BDF1 mouse allografted with mouse P388 cells administered qd for 5 days,Other,671464.0,
717,1148476,1,1,,103166066,2179,Unspecified,,,,,Toxicity in ip dosed BDF1 mouse allografted with mouse L1210 cells administered qd for 5 days,Other,671464.0,
718,1148477,1,1,,103166066,2179,Unspecified,,,,,"Lipophilic-hydrophilic balance, Rm of the compound by reversed-phase chromatographic analysis",Other,671464.0,
719,1149743,1,1,,103166066,2179,Unspecified,,,,,Half life in mouse L1210 cells allografted C3H/DBA2 F1 hybrid hybrid mouse,Other,894684.0,
720,1149744,1,1,,103166066,2179,Unspecified,,,,,"Retardation factor, Rm of the compound by reversed phase partition chromatography",Other,894684.0,
721,1149745,1,1,,103166066,2179,Unspecified,,,,,Toxicity in sc implanted mouse L1210 cells allografted C3H/DBA2 F1 hybrid hybrid mouse assessed as optimum dose required to increase life span treated ip after 24 hrs after tumor inoculation and continued for 5 days,Other,894684.0,
722,1149746,1,1,,103166066,2179,Unspecified,,,,,Antileukemic activity against sc implanted mouse L1210 cells in C3H/DBA2 F1 hybrid hybrid mouse assessed as increase life span treated ip after 24 hrs after tumor inoculation and continued for 5 days,Other,894684.0,
723,1149747,1,1,,103166066,2179,Unspecified,,,,,Antileukemic activity against ip implanted mouse L1210 cells in C3H/DBA2 F1 hybrid hybrid mouse assessed as increase life span treated ip after 24 hrs after tumor inoculation and continued for 5 days,Other,894684.0,
724,1150556,1,1,,103166066,2179,Unspecified,,,,,Antitumor activity against mouse L1210 cells allografted in ip dosed C3H/DBA2 F1 mouse assessed as optimum dose required to increase in maximum life span administered as qd for 5 days,Other,950644.0,
725,1150557,1,1,,103166066,2179,Unspecified,,,,,"Antitumor activity against mouse L1210 cells allografted in C3H/DBA2 F1 mouse assessed as increase in life span at optimum dose, ip qd administered for 5 days relative to control",Other,950644.0,
726,1159550,3,1,,252402213,2179,Inactive,12653201.0,5226.0,,,Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening,Screening,26479318.0,
727,1159580,2,1,,268737876,2179,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
728,1159607,2,1,,313042045,2179,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
729,1159620,1,1,,103166066,2179,Active,,,,,Summary of drug indications.,Other,,
730,1197848,1,2,,103166066,2179,Active,13959709.0,7153.0,,,Stabilization of recombinant human topoisomerase 2-pBR322 DNA cleavage complex assessed as linear DNA formation at 10 uM after 60 mins by agarose gel electrophoresis,Other,25626146.0,
731,1224859,2,1,,90341308,2179,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
732,1259407,1,1,,363898977,2179,Inactive,,,,,CCRIS mutagenicity studies,Other,,
733,1259408,1,1,,363897409,2179,Active,,,,,GENE-TOX mutagenicity studies,Other,,
734,1259411,1,1,,363898977,2179,Active,,,,,CCRIS carcinogenicity studies,Other,,
735,1259416,1,2,,340079512,2179,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
736,1259416,1,2,,340079513,2179,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
737,1259421,1,1,,340079512,2179,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
738,1259421,1,1,,340079513,2179,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
739,1259423,1,2,,354755832,2179,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
